Covalent Modification that Enhances Protein Properties and Functions and Folds Random Coil into Alpha-Helix by Prashar, Deepali
Syracuse University 
SURFACE 
Chemistry - Dissertations College of Arts and Sciences 
8-2012 
Covalent Modification that Enhances Protein Properties and 
Functions and Folds Random Coil into Alpha-Helix 
Deepali Prashar 
Syracuse University 
Follow this and additional works at: https://surface.syr.edu/che_etd 
 Part of the Chemistry Commons 
Recommended Citation 
Prashar, Deepali, "Covalent Modification that Enhances Protein Properties and Functions and Folds 
Random Coil into Alpha-Helix" (2012). Chemistry - Dissertations. 191. 
https://surface.syr.edu/che_etd/191 
This Dissertation is brought to you for free and open access by the College of Arts and Sciences at SURFACE. It has 
been accepted for inclusion in Chemistry - Dissertations by an authorized administrator of SURFACE. For more 
information, please contact surface@syr.edu. 
 
 
 
 
ABSTRACT 
Understanding the fundamental science of aggregation and surface adsorption of proteins is 
critical for developing protein-based drugs, understanding aggregation-induced diseases and for 
preventing biofouling that impacts a wide range of industries. In spite of the advances in 
sensitive and high-throughput analytical methods, the commercialization of protein drugs has 
been impeded by poor solubility, inevitable aggregation, and difficulty in purification. The 
primary aim of this dissertation is to modify proteins covalently to induce folding in random coil 
sequences, prevent aggregation, surface adsorption and for increasing the thermal stability 
against aggregation of proteins.  
The first chapter describes the chemistry for modifying the lysine residues in proteins with 
alditols (organic kosmotropes), via an amide bond using the traditional N-hydroxysuccinimide 
(NHS) activated carboxylic acids or via an efficient water-driven ligation generating a 
squaramide linkage. Conjugating such organic kosmotropes to proteins via a squaramide linkage, 
results in the formation of a hydrolytically stable bond together with higher amount of 
modification when compared to amide bond formation using NHS-activated carboxylic acids. 
The second chapter presents a general approach for preventing both protein aggregation and 
surface adsorption by modifying proteins with β-cyclodextrins (βCD) via a squaramide linkage. 
As compared to native unmodified proteins, the β-cyclodextrin-modified proteins (lysozyme and 
RNase A) exhibited significant reduction in aggregation, surface adsorption and increase in 
thermal stability against aggregation. 
The third chapter describes the covalent modification of a random coil mutant (L44A) of the 
coiled coil domain of cartilage oligomeric matrix protein (COMPcc) with squarate derivatives. 
The covalent modification with βCD-amino squarates or methyl squarate alone folded the 
random coil into an α-helix. The COMPcc is capable of binding small molecule such as 
 
 
 
 
curcumin, retinol and vitamin D. Curcumin exhibited an increase in the fluorescence signal upon 
binding to L44A-(βCD)n as compared to the wild type protein suggesting that the folding 
stability of L44A is either enhanced or preserved.  
The fourth chapter describes the synthesis and development of an adamantane-platinum 
conjugate (analog of carboplatin) hosted in β-cyclodextrin. This inclusion complex formed by 
βCD and the adamantane-platinum conjugate exhibited higher cytotoxicity towards 
neurobalstoma (SK-N-SH) cells than carboplatin. This approach provides versatility for 
enhancing drug properties via structural modification and targeted delivery using protein-drug 
conjugates. 
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Chapter 1 
A Kosmotrope Approach for Prevention of Protein Aggregation 
 
Summary 
Protein structural instability, misfolding, and aggregation are significant challenges faced by 
the biopharmaceutical industries. There is no well-proposed theory for prevention of protein 
aggregation. This section of the dissertation is based on the hypothesis that modifying proteins 
with kosmotropes can help prevent protein aggregation. This hypothesis is based on the century 
old-observation that certain ions classified as “kosmotropes” preserve protein structure, whereas 
other ions classified as “chaotropes” tend to denature protein structure. Amine groups on 
surfaces are believed to be chaotropic in character and are responsible for non-specific 
adsorption of proteins on surfaces. I hypothesize that the lysine residues on the surface of 
proteins are potentially chaotropic in character and may be responsible for protein aggregation. 
Hence, modifying the lysine residues with “organic kosmotropes” can mask the chaotropic 
character of the lysine residues and can prevent protein aggregation. To test this hypothesis, the 
lysine residues of proteins like lysozyme were modified with non-natural sugar alcohols 
(alditols), via an amide bond and a squaramide linkage. Although modification of lysozyme with 
alditols via amide bond was successful, the extent of modification was low due to the hydrolytic 
instability of the amide bond. Lysozyme modified with D-mannitol via squaramide linkage using 
squarate-based reagents exhibited much higher degree of modification compared to the amide 
bond formation. Hence, squarate based chemistry provides a great opportunity to modify proteins 
with sugars using a stable bond. 
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1.1 Background and Significance 
1.1.1 Proteins as pharmaceutical drugs 
Proteins and nucleic acids have long been used as biopharmaceutical drugs for treatment of 
diseases.
 
The development and manufacturing of protein therapeutics is increasing each year 
with the product required globally and the number of new drugs undergoing clinical trials.
1 
Amidst the great therapeutic potential of peptide or protein-based drug candidates, 96% are 
abandoned during preclinical or clinical development due to solubility or aggregation issues.
2
 
The stability and efficacy of the protein drugs is often lost during production cycle and storage 
due to self- association leading to formation of aggregates.
3 
Aggregation can possibly occur 
during any of the multiple stages of protein drug processing including fermentation, purification, 
formulation, and even storage, which are conditions that would subject the proteins under stress.
4 
Apart from potential decrease in efficacy and  reduced bioavailability, aggregation of protein 
therapeutics can even lead to serious detrimental effects such as renal failure
5
 and 
immunogenicity.
6
 The surface adsorption of protein drugs also causes loss of efficacy of 
therapeutic proteins in syringes for intravenous delivery. Preventive strategies can help to 
overcome these degradative pathways and ensure efficacy and stability of protein therapeutics.
7-8
  
1.1.2 The kosmotrope theory – a new basis for preventing protein aggregation 
Certain compounds such as glycerol, sucrose and polyethylene glycol can increase the stability 
of proteins when present in solution. Different theories have been proposed to rationalize how 
the native protein structure is stabilized in solution by such additives.
9
 In 1888, Franz Hofmeister 
described the effect of salts on protein solubility and arranged salts in the order of their ability to 
either salt protein out of solution or salt protein into solution. This series came to be known as 
the Hofmeister series (Figure 1.1).
10
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Figure 1.1 The ions (cations or anions) towards the right are called chaotropes and act to salt 
proteins into solution, whereas ions to the left are called kosmotropes and act to salt proteins out 
of solution. 
Certain ions stabilize protein structure or salt proteins out of solution and are classified as 
kosmotropes, whereas other ions destabilize protein structure or salt proteins into solution and 
are classified as chaotropes. The idea of such ions present as solutes in protein solutions was 
extended to small organic molecules called osmolytes produced by bacteria, plants and fish to 
combat osmotic stress.
11
 Osmolytes are believed to be kosmotropic for their ability to preserve 
the naturally folded structure and function of proteins. The mechanism of the Hofmeister effect 
is largely empirical and not entirely understood. Considering the effect of additives on protein 
folding, recent studies suggest that while kosmotropic anions stabilize protein structures by 
direct interactions,
10, 12-16
 the effect of nonionic organic osmolytes on proteins is likely indirect.
9  
1.1.3 Drawbacks of protein PEGylation 
Modifying proteins covalently with poly(ethylene glycol) (PEG) is called protein PEGylation 
and is a process of growing interest to enhance the therapeutic activity of proteins. PEG modified 
proteins possess reduced toxicity, immunogenicity and proteolysis; reduced rates of kidney 
clearance; and enhanced stability and solubility.
17
 PEGylation not only increases the stability of 
proteins but can also prevent protein aggregation.
18
 Jiang and co-workers have reported the 
conjugation of α-chymotrypsin with poly(ethylene glycol) and zwitterionic polymers such as 
poly(carboxybetaine)(pCB). They report that conjugation with pCB improves the stability in a 
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manner similar to PEGylation, but the pCB conjugates retain or even improve the binding 
affinity as a result of enhanced protein-substrate hydrophobic interaction.
19
 Poly(ethylene glycol) 
(PEG) being a synthetic polymer is polydispersed,
20  
and the multiple ether groups of  the PEG 
units can form undesired complexes with metal ions and lead to medical complications in vivo.
21
 
Considering the diverse structures and properties of proteins, a different and competent 
chemistry for preventing protein aggregation and surface adsorption is highly desired.  
1.1.4 Protein adsorption and denaturation 
Denaturation is the alteration of the three-dimensional structure of a protein when subjected to 
some form of stress such as heat, acid or alkali, in such a way that it will no longer be able to 
carry out its function. Denatured proteins can exhibit a wide range of characteristics ranging 
from loss of solubility to aggregation.
22
 Proteins have a high tendency to denature to facilitate 
hydrophobic interaction between their non-polar residues and their environment, such as a 
hydrophobic surface. Protein adsorption on a surface is a complex process, and involves 
multistep processes. Regardless of the nature of the surface, protein adsorption involves among 
other processes a) reversible adsorption of the native protein, b) partial denaturation and 
orientation change, c) desorption of the partially denatured protein from the surface and d) 
complete denaturation and immobilization on the surface.
23-24
 Since protein aggregation and 
surface adsorption are intimately associated with protein denaturation, I have explored a general 
working hypothesis, that covalent modification of proteins with kosmotropic organic molecules 
can help prevent protein aggregation and surface adsorption.  
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1.1.5 Strategies and theories for preventing protein aggregation 
Self-assembled monolayers (SAMs) presenting polyols such as D-mannitol are known to 
prevent protein adsorption on gold surface.
25
 It is believed that SAMs presenting polyols such as 
D-mannitol can directly template a structured interfacial water layer, which makes the surface 
invisible to a solvated protein.
25-27
 Using the same hypothesis, covalent modification of proteins 
with polyols can help template a structured interfacial water layer around a protein making one 
protein invisible to the other and thus preventing protein aggregation (Figure 1.2).  
 
Figure 1.2 Schematic illustrations for (A) unmodified proteins aggregating in solution, (B) 
Proteins modified with kosmotropes in solution prevents aggregation by templating a structured 
interfacial water layer around each protein. 
Surfaces presenting amines are known to promote non-specific adsorption of proteins.
28
 I 
hypothesize that the potentially chaotropic character of the lysine residues in proteins is 
responsible for protein aggregation.
29
 The contribution of lysine residues to the stability of 
proteins also depends on the nature of counter anions.
9, 13-15, 30-32
 Thus, utilizing the large 
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abundance of the lysine residues in proteins and their chemical reactivity, modifying the lysine 
residues in proteins may help increase protein stability.
33 
 
1.2 Results and Discussion 
1.2.1 Synthesis of alditol-terminated carboxylic acids  
I synthesized D-gulitol-terminated carboxylic acid to modify the lysine residues of lysozyme 
via an amide bond using N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) (EDC) chemistry (Scheme 1.1). Luk and co-workers have suggested that SAMs 
formed by enantiomeric and diastereomeric alditol-terminated alkanethiols on gold template a 
different interfacial water structure and hence have different ability to resist protein adsorption 
and mammalian cell adhesion.
34
 Based on these results, the enantiomeric L-gulitol-terminated 
carboxylic acid was also synthesized (Scheme 1.2) using procedures similar to those used for the 
synthesis of D-gulitol-terminated carboxylic acid and was further used for covalent modification 
of lysozyme.   
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Scheme 1.1 Covalent modification of lysozyme with D-gulitol-terminated carboxylic acid (6) 
using NHS/EDC coupling 
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The synthesis of molecule 6 is given Scheme 1.1. Briefly, compound 3 was synthesized by 
literature reported procedures. 
35
 Nucleophilic substitution on 4-bromovaleronitrile with 
compound 3 afforded compound 4. Hydrolysis of compound 4 in ethanolic NaOH afforded the 
acid 5. Deprotection of the acetonide groups in compound 5 with 1N HCl provided the D-gulitol-
terminated carboxylic acid, 6. Treatment of lysozyme with activated carboxylic acid 6 (prepared 
in situ with EDC and NHS) afforded the product 7.  
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Scheme 1.2 Covalent modification of lysozyme with L-gulitol-terminated carboxylic acid (13) 
using NHS/EDC coupling 
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1.2.2 ESI-MS confirms lysozyme modification with D-gulitol 
Electron spray ionization mass spectroscopy (ESI-MS) was used to monitor the degree of 
modification of lysine residues in the protein lysozyme with D-gulitol. Mass spectra showed that 
one (lysozyme-(D-gulitol)1) or two (lysozyme-(D-gulitol)2) lysine residues were modified on the 
protein with D-gulitol. The mass corresponding to the dimer of unmodified lyozyme was also 
observed. Such dimer formation is likely due to the aggregation of the unmodified proteins. 
Interestingly, mass corresponding to the dimer for lysozyme-(D-gulitol)n was not observed 
(Figure 1.3). This result is consistent with the hypothesis that modifying proteins with organic 
kosmotropes can prevent protein aggregation.  
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Figure 1.3 ESI-MS spectra of lysozyme-(D-gulitol)n (n can range from 1 to 6), indicating that up 
to two lysine residues in lysozyme were modified with D-gulitol. Peak for the unmodified 
lysozyme and dimer of unmodified lysozyme was also observed. 
To further characterize the products of lysozyme modification with the alditols, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted on lysozyme 
modified with D-gulitol. However, no separate bands for lysozyme or modified lysozyme 
(lysozyme-(D-gulitol)n, (n can range 1 to 6) were observed on the SDS-PAGE. This may be due 
to the very small difference in mass between unmodified lysozyme and lysozyme-(gulitol)n, 
making the resolution of the individual bands impossible (Figure 1.4).  
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Figure 1.4 Gel image from SDS-PAGE for lysozyme modified with D-gulitol. Unmodified 
lysozyme (Lane 1), sample containing mixture of unmodified lysozyme and lysozyme-(D-
gulitol)n (Lanes 2 and 3). No separate bands corresponding to different modifications of 
lysozyme with D-gulitol were observed. 
1.2.3. Squaramide is a stable linkage compared to amide bond  
Luk and coworkers have reported that chemoselective reaction between amino squarate 
derivatives and the amino acid cysteine or unprotected peptides with N-terminus cysteine 
proceeds efficiently in aqueous media at physiological pH. Amino squarate derivatives reacted 
exclusively with cysteine at neutral pH in water containing a mixture of five amino acids (L-
cysteine, L-serine, glycine, L-tyrosine, and L-lysine). As the pH was increased to 8.5, L-lysine 
also started to react suggesting that the rate of reaction for L-lysine with the amino squarate 
derivative increases with increasing pH. It is believed that the substitution reaction of squarate 
reagents with nucleophiles in water is enhanced by the high dielectric constant and hydrogen 
bonding ability of water (Figure 1.5).   
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Figure 1.5 Hydrogen bonding ability and high dielectric constant of water increases the stability 
of zwitterionic resonance structure and electrophilicity of squarate in water versus organic 
solvent. 
While amino squarates are reported to be stable against hydrolysis in water and in the presence 
of esterases and cell lysates, 
36
 amide bond formed using derivatives of (NHS)-activated 
carboxylic acids are prone to hydrolysis in water. Hence conjugating organic kosmotropes to 
proteins using a squaramide bond rather than an amide bond may be a better method to achieve a 
hydrolytically stable linkage with high degree of modifications. 
Scheme 1.3 Covalent modification of lysozyme with N-allyl squaramide using compound 15 
 
 
 
A model reaction was run where lysozyme was modified covalently with N-allyl O-phenoxy 
amino squarate, 15 (Scheme 1.3).
37
 The primary amine groups of the lysines in lysozyme can 
displace the phenoxy group bonded to the reactive N-allyl amino squarate moiety in compound 
OO
N
H
+
H2N
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N
H
aqueous buffer
      pH 7.8
HN
15
lysozyme
lysozyme
O
12 
 
 
 
15. This conjugation reaction was conducted at slightly basic pH of 7.8 in PBS buffer with the 
aim of keeping the lysine residues potentially deprotonated (pKa of lysine side chain is 10.53).  
 
 
Figure 1.6 ESI-MS spectra for lysozyme-(N-allyl squaramide)n indicating that up to three lysine 
residues are modified with N-allyl squaramide with a relatively small mass peak for unmodified 
lysozyme. 
 
The ESI-MS spectra of lysozyme-(N-allyl squaramide)n showed that up to three lysine residues 
were successfully modified with N-allyl squaramide at pH 7.8 (Figure 1.6). Interestingly, the 
peak for unmodified lysozyme was smaller in comparison to the peaks of lysines modified with 
N-allyl squaramide. Since modification of lysozyme using N-allyl O-phenoxy amino squarate, 
(15) was successful, I attempted to modify the lysine residues in lysozyme with compound 16
37
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in which D-mannitol was conjugated to a phenoxy squarate moiety (Scheme 1.4). This approach 
would ensure that the potentially kosmotropic polyol D-mannitol, is conjugated to the protein via 
a squaramide linkage which is hydrolytically more stable than the amide bond formation using 
the NHS activated carboxylic acids. 
Scheme 1.4 Covalent modification of lysozyme with compound 16 
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Matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry 
was used to determine the degree of modification of the lysine residues in lysozyme with 
compound 16. The modification of the lysine residues with compound 16 was compared to the 
degree of modification of the lysine residues with compound 6. Interestingly, the intensity of the 
product peaks in the mass spectrum corresponding to different degree of modification of the 
lysine residues with compound 16 was higher than those observed with compound 6 (Figure 1.7). 
In addition, the peak for unmodified lysozyme was very small. Hence, this chemistry provides a 
great opportunity to modify proteins with sugars efficiently via the squaramide bond.  
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Figure 1.7 MALDI-TOF spectra for (A) lysozyme modified with compound 16 indicating that 
up to two lysine residues in lysozyme are modified with D-mannitol squaramide and a relatively 
small mass peak for unmodified lysozyme. (B) lysozyme modified compound 6 using NHS/EDC 
chemistry showing that only one lysine residue is modified with D-gulitol. 
1.2.4 Purification of alditol modified lysozyme 
In order to study the stability of proteins against denaturation and aggregation, it is imperative 
to separate the modified protein from the unmodified protein. The cis-diol groups in ribonucleic 
acid as well as other sugars are known to form complexes with borate anion. This property has 
been exploited to effect chromatographic separation of nucleosides, oligonucleotides and tRNA 
by using dihydroxyborylphenyl groups attached covalently to cellulose,
38-40 
methacrylic acid 
polymer,
41 
or polyacrylamide.
42
 Based on the same principle, the cis-diols of the alditols can 
potentially bind to borate anion and allow separation of proteins grafted with alditols from 
unmodified proteins. The science of preparation of biocompatible porous hydrogels based on 
polymer stabilization of lyotropic liquid crystal phase has been developed in Luk laboratory.
43-44
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Such porous hydrogels with pendant boronic acid groups can be used for the isolation and further 
purification of proteins modified with alditols (Figure 1.8). 
 
Figure 1.8 Strategy for purifying proteins modified with alditols using boronic acid-laden porous 
hydrogels. 
Boronic acid monomer, (18) was synthesized using literature reported procedure (Scheme 
1.5).
45
 Boronic acid-laden porous hydrogels were prepared and lysoyzme-(D-gulitol)n was treated 
with these hydrogels for 24 h. After 24 h, it was expected that lysoyzme-(D-gulitol)n would bind 
to the pendant borate ion on the hydrogel. The hydrogel was isolated and further washed with 
buffer (PBS, pH 5.0) to displace lysoyzme-(D-gulitol)n. Analysis of the isolated protein sample 
by ESI-MS indicated that purified lysozyme-(D-gulitol)n was not obtained. The failure to isolate 
purified lysozyme-(D-gulitol)n using the above strategy could be either due to insufficient 
modification of lysozyme with D-gulitol or the inadequate binding of the cis-diols of the alditols 
covalently attached to lysozyme.  
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Scheme 1.5 Synthesis of boronic acid monomer (18) 
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High performance liquid chromatography (HPLC) was also used to attempt the separation of 
lysozyme-(D-gulitol)n from unmodified lysozyme. However, the purified protein could not be 
obtained probably due to the small mass difference between modified and unmodified proteins. 
1.2.5 Cyclodextrins- another class of organic kosmotropes  
Cyclodextrins have been reported to stabilize protein structure and aid in protein folding.
46-48
 
Cyclodextrins are another class of organic kosmotropes, which have rigid structures and 
conformations. When covalently conjugated to proteins the multiple hydroxyl groups of 
cyclodextrins can act as a template to build a structured solvation shell around the protein and 
help prevent protein aggregation. The ability of cyclodextrins to prevent protein aggregation and 
surface adsorption will be discussed in detail in chapter 2 of this dissertation. β-cyclodextrin 
(βCD) has a mass close to 1.1 kDa. Thus, based on the difference in mass between unmodified 
proteins and proteins modified with βCD, one can potentially effect the separation of modified 
proteins from unmodified proteins and isolate individual modifications as well.      
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1.3 Conclusion and Perspectives 
The work presented in this section of the dissertation explores the hypothesis that modifying 
proteins with organic molecules (organic kosmotropes) can stabilize native protein structure, can 
also prevent protein aggregation and surface adsorption. Lysine residues are believed to be 
chaotropic and hence are considered responsible for protein aggregation. The chaotropic lysine 
residues in lysozyme were modified with non-natural sugar alcohols such as D- and L- gulitol 
using NHS/EDC chemistry. This was done by forming amide bonds with the primary amine 
groups of the lysine residues. I discovered that conjugating organic kosmotropes to proteins 
using squaramide derivatives is a better method than making hydrolytically unstable derivatives 
of (NHS)-activated carboxylic acids. Interestingly, MALDI-TOF spectra showed that the 
intensity of the peaks corresponding to different degree of modification of the lysine residues 
using amino squarate conjugated to the polyol D-mannitol, was higher than what was observed 
when lysozyme was modified with the polyols D-gulitol or L-gulitol using NHS/EDC chemistry. 
This new squaramide based conjugation chemistry hence provides an opportunity to modify 
proteins with sugars efficiently with a hydrolytically stable bond. Modification of proteins with 
larger kosmotropes such as cyclodextrins will be described in the following chapters of this 
dissertation. 
1.4 Experimental section 
Materials and Methods 
Chemicals. Chicken egg white lysozyme (catalog number L6876) was obtained from 
SigmaChemical Company (St. Louis, MO) and were used without further purification. Sinapinic 
acid was obtained from ProteoChem (Denver, 105 CO). Phosphate buffered saline, PBS (2.7 mM 
potassium chloride, 137 mM sodium chloride, 8 mM sodium phosphate dibasic, 1.48 mM  
18 
 
 
 
potassium phosphate monobasic), was used for all protein reactions unless stated otherwise (pH 
of the prepared buffers was adjusted using 1 N HCl and 1 N NaOH). Ammonium persulfate 
(APS 99 + %), 3-(trimethoxysilyl) propyl methacrylate, 98% were purchased from Acros 
Organics USA (Morris Plains, NJ). N,N,N’,N’-Tetramethylethylenediamine (TEMED) was 
purchased from Sigma Chemical Company (St. Louis, MO). N,N’-Methylenebisacrylamide (bis-
acrylamide) was purchased from Fluka Chemicals (Milwaukee, WI). Acrylamide was purchased 
from MP Biomedicals (Solon, OH). All other chemicals were obtained from Aldrich Chemicals 
(Milwaukee, WI). Water used for preparing all buffers and solutions had resistivity of 18 MΩ cm 
(Millipore, Billerica, MA). 
General Methods for Synthesis 
The processes involving reactants sensitive to moisture or air were executed under an 
atmosphere of argon using oven-dried glassware. Reagents and solvents were reagent grade and 
used as supplied unless otherwise mentioned. Solvents were distilled under reduced pressure 
using Buchi rotary evaporator below 40 
o
C. EMD Silica Gel 60 F254 precoated plates (0.25-mm 
thickness) were used for TLC and a solution of phosphomolybdic acid/ceric sulfate/sulfuric acid 
(10g : 1.25g : 8% 250 mL), followed by charring at ~ 150 °C, was used for visualization. Flash 
column chromatography was performed using SILICYCLE, Silia-P Flash Silica Gel with 40-63μ 
mesh size. 
1
 H, 
13
 C NMR spectra were recorded on 300 MHz, 
1
H chemical shifts are reported in 
ppm relative to CDCl3 δ 7.26, MeOH δ 4.87, 3.31 and δ D2O 4.80. 
13
C chemical shifts are 
reported relative to CDCl3 δ 77.23, MeOH δ 49.15 and (High Resolution Mass Spectra) HRMS 
was recorded by positive ion electrospray on a Bruker 12 Tesla APEX –Qe FTICR-MS with 
Apollo II ion source. Protein ESI-MS spectra were obtained on Mass spectrometer: ESI-Q-TOF 
II (Waters, Milford, MA, USA) Electrospray: Nanoflow-LC ESI.  
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Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was conducted using 15% separating gel (3.4 mL of water, 7.5 mL of 30% gel 
concentrate, 3.8 mL of 1.5 M Tris buffer, pH 8.8, 0.15 mL of 10% sodium dodecyl sulfate 
(SDS), 0.15 mL of 10% ammonium persulphate (APS) and 6.0 µL of 
tetramethylethylenediamine (TEMED) and 3% stacking gel (1.32 mL of water, 30% gel 
concentrate, 0.5 mL of tris buffer, pH 6.8, 0.24 mL of 10% SDS, 0.04 mL of ammonium 
persulfate and 2.4 µL of TEMED).  The 3% staking gel was slowly poured over the 15% 
separating gel and the comb was gently inserted before the gel polymerized. After 30 min, the 
comb was removed slowly to load the protein samples in the gel. The protein sample (15 µL, 0.5 
mg/mL) was mixed with 10 µL 0.25% of bromophenol blue (BPB) and loaded on the gel. A 
protein ladder, (Precision Plus Dual Color from BIO-RAD (BIO-RAD, Hercules, CA) was added 
in one of the wells for molecular weight reference. Tris-glycine (1×) was used as the running 
buffer for gel electrophoresis. The gels were run at 30 V for 3 h.  The gel was stained with 
coomassie blue for 24 h and then destained in deionized water overnight. The image of the gel 
was taken on the Alpha DigiDoc (Alpha Innotech, San Leandro, CA). 
 
Dialysis  
The protein samples were dialyzed in 1× PBS (dialysis media), using Slide-A-Lyzer Dialysis 
Cassettes 7K molecular weight cut off (MWCO) purchased from Thermo Scientific (Rockford, 
IL). Before use, the Slide-A-Lyzer Dialysis Cassette was hydrated in the dialysis media for 5 
min. The sample was injected in the cassette and placed in 250 mL of dialysis media to eliminate 
unreacted compound 6. The buffer was changed twice every 2 h for 6 h and then left overnight, 
20 
 
 
 
after which time the sample was removed from the dialysis cassette and protein sample was 
analysed by MALDI-TOF or ESI-MS. 
Polymerization of Boronic Acid Monomers into Hydrogels 
Hydrogels were prepared in 2 mL vials (1.25 cm × 4.5 cm) blown with nitrogen gas.  
Polymerization of boronic acid monomers into hydrogels was done by addition of 0.4% w/w of 
APS (from 40% w/w stock solution prepared in water) and bis-acrylamide (from 2% w/w stock 
solution in water) as a crosslinker, to 6% w/w of boronic acid monomers (50% w/w stock 
solution of compound 17 and acrylamide in water). The sample was vortexed for 1 min, followed 
by the initiation of polymerization by addition of 0.2% w/w of TEMED (from 20% w/w stock 
solution prepared in water). TEMED accelerates the polymerization reaction by catalyzing the 
formation of free radicals from APS.
49-51
 The sample was left undisturbed at rt for 24 h to allow 
complete polymerization.  
Synthetic procedures and Spectral data 
The synthetic procedures and spectral data for the compounds successfully synthesized are given 
below:  
Synthesis of compound 2 
O O
OO
2
O
O
 
To a solution of D-(-)-gulonic-γ-lactone (3.00 g, 16.8  mmol) in dry acetone (30 mL) was added 
2, 2-dimethoxypropane (10.0 g, 96.0 mmol) and added TsOH monohydrate (catalytic amount). 
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The mixture was heated at 50 °C for 3 h. Reaction was quenched with 0.2 mL of triethylamine. 
Crude product was obtained as a white solid after evaporation of solvent.  The crude product was 
purified using silica gel column (35% EtOAc in Hexane) to give compound 2 (2.84 g, 65%) as a 
white solid. Rf = 0.56, (50% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 4.84-4.71 (m, 
2H), 4.45-4.41 (m, 2H), 4.24-4.21 (m, 1H), 3.84-3.76 (m, 1H), 1.43 (s, 3H), 1.41 (s, 3H), 1.39 (s, 
3H), 1.37 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 173.0, 114.9, 110.7, 81.1, 76.2, 75.9, 75.4, 
65.4, 26.9, 26.8, 26.1, 25.4. HRMS found 281.0990 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 
281.0995. 
Synthesis of compound 3 
OH
OH
OO
3
O
O
 
To an ice cooled solution of compound 2 (2.84g, 11.0 mmol) in MeOH (28 mL), NaBH4 (1.45 g, 
38.5 mmol) was added portion wise with stirring. The mixture was stirred at rt for 2 h. While 
cooling the reaction mixture in an ice bath with vigorous stirring, 1.0 M AcOH solution in water 
was added drop wise to neutralize the mixture. After evaporation of solvents the residue was 
suspended in brine and extracted with EtOAc until TLC showed no product in the aqueous 
phase. The combined organic phase was dried over anhydrous Na2SO4 to obtain the crude 
product as colorless oil after evaporation of solvent. The crude product was purified using silica 
gel column (75% EtOAc in Hexane) to give compound 3 (2.454 g, 85%) as a colorless oil. Rf = 
0.25 (80% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 4.27-4.21 (m 2H), 4.21-4.02 (m, 
2H), 3.85-3.74 (m, 4H), 3.02 (br s, 1H), 1.50 (s, 3H), 1.43 (s, 3H), 1.36 (s, 3H), 1.35 (s, 3H). 
13
C 
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NMR (75 MHz, CDCl3): δ 109.8, 108.8, 77.62, 76.9, 76.2, 73.6, 69.8, 66.1, 61.1, 27.1, 26.7, 
25.4, 25.2, 20.0. HRMS found = 285.1300 [M + Na]
+
, calcd for [C12H18O6+Na] 
+ 
= 285.1308. 
Synthesis of compound 4 
 
 
 
Compound 3 (2.45 g, 9.36 mmol) was dissolved in THF (24 mL) and the solution was, cooled to 
-75 
o
C and charged with NaH (0.430 g, 60% by wt in mineral oil, 17.9 mmol). The temperature 
was allowed to rise to 0
 
°C slowly and the mixture was allowed to stir at 0 °C for 90 min. Then 
5-bromovaleronitrile (1.82 g, 11.2 mmol) was added drop wise. The mixture was allowed to stir 
at rt for 2 d. The reaction was quenched with water and extracted with EtOAc. The organic phase 
was dried over anhydrous Na2SO4. The crude product was obtained as colorless oil after 
evaporation of solvent. The crude product was purified using flash silica gel column (70% 
EtOAc in Hexane) to obtain compound 4 (1.276 g, 56%) as colorless oil. Rf = 0.52 (80% EtOAc 
in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 4.27-4.04 (m, 2H), 4.03-3.95 (m, 2H), 3.78-3.45 (m, 
5H), 2.75 (d, JH-H = 6.49, 1H,), 1.67-1.66 (m, 2H), 1.43 (m, 3H), 1.37 (m, 3H), 1.30 (m, 3H), 1.29 
(m, 3H).
 13
C NMR (75 MHz, CDCl3): δ 119.6, 109.6, 108.8, 105.9, 77.7, 77.3, 77.0, 76.9, 76.4, 
75.9, 74.4, 70.6, 69.8, 69.7, 68.9, 66.0, 54.6, 29.7, 28.5, 27.0, 26.6, 25.4, 25.1, 22.5, 17.0. HRMS 
found = 366.1884[M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 366.1887. 
 
OH O
OO
O
CN
4
O
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Synthesis of compound 5 
OH
O
OO
O
COOH
5
O
 
To a solution of compound 4 (1.27 g, 3.71 mmol) in EtOH (60 mL) added 25 N NaOH (13 mL) 
was heated under reflux for 18 h. Reaction mixture was neutralized using concentrated HCl. 
Solvent was evaporated under reduced pressure to yield a white residue. The residue was washed 
with THF and the washings were filtered through a pad of celite. The crude product was obtained 
as colorless oil after evaporation of solvent. The crude product was purified using flash silica gel 
column (50% EtOAc in Hexane and then eluting the pure compound in MeOH) to obtain 
compound 5 (0.987, 73%) as a colorless oil. Rf = 0.21 (80% EtOAc in Hexane). 
1
H NMR (300 
MHz, CDCl3): δ 4.30-4.22 (m, 2H), 4.07-4.02 (m, 2H), 3.83-3.58 (m, 4H), 3.47 (br s, 2H), 2.25 ( 
br s, 2H) 1.93 (br s, 1H), 1.60 ( br s, 4H), 1.49 (m, 3H), 1.43 (m, 3H), 1.36 (m, 3H), 1.34 (m, 
3H).
 13
C NMR (75 MHz, CDCl3): δ 109.8, 108.9, 76.9, 75.9, 71.7, 70.1, 69.2, 66.1, 35.1, 29.1, 
27.0, 26.6, 25.4, 25.2, 22.0. HRMS found = 385.1828[M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 
385.1832. 
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Synthesis of compound 6 
6
OH
O
OHHO
HO
COOH
HO
 
Compound 5 (0.987 g, 2.72 mmol) was suspended in 15 mL of 1N HCl and refluxed for 1 h. The 
reaction mixture was brought to rt and neutralized by adding 1N NaOH drop wise. Solvent was 
evaporated to yield a white residue. The residue was washed with THF and the washings were 
filtered through a pad of celite. The filtrate was concentrated to yield compound 6 (0.376 g, 
49%) as a hygroscopic solid. 
1
H NMR (300 MHz, CDCl3): δ3.97-3.30 (m, 10H), 2.27-2.25 (br 
m, 2H), 1.64 (br s, 4H). 
13
C NMR (75 MHz, CDCl3): δ 180.2, 73.8, 72.9, 72.1, 70.9, 70.4, 69.1, 
65.7, 63.0, 35.0, 29.0, 22.0, 14.2. HRMS found = 305.1206 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+
=305.1206. 
Conjugation of lysozyme with compound 6 
OH O
OHHO O
H
N
7
HO
HO
Lysozyme
 
Added 0.30 mg EDC and 0.20 mg of NHS, to 1.00 mg of compound 6 dissolved in 2-(N-
morpholino)ethanesulfonic acid (MES) buffer, at pH 6.0. Compound 6 was reacted with NHS 
and EDC for 15 min at rt. To the reaction mixture added 0.70 µl of mercaptoethanol to quench 
excess of EDC. Added 500 µL of 1 mg/mL solution of lysozyme in MES buffer at pH 6.0, and 
the protein reaction was run at rt for 2 h. The protein reaction was then dialysed in PBS buffer, 
25 
 
 
 
pH 7.4, to eliminate unreacted reagents. Degree of protein modification was analysed by ESI-
MS. 
Synthesis of compound 9 
O O
OO
9
O
O
 
To a solution of L-(+)-gulonic-γ-lactone (2.00 g, 11.2 mmol) in dry acetone (40 mL) added 2, 2-
dimethoxypropane (6.66 g, 64.0 mmol) and TsOH monohydrate (catalytic amount). The mixture 
was heated at 50 °C for 3 h. Reaction was quenched with 0.1 ml of triethylamine. Crude white 
solid was obtained after evaporation of solvent.  The crude product was purified using silica gel 
column (35% EtOAc in Hexane) to give compound 9 (1.99 g, 69%) as a white solid. Rf = 0.56, 
(50% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 4.84-4.72 (m, 2H), 4.45-4.39 (m, 2H), 
4.24-4.19 (m, 1H), 3.84-3.79 (m, 1H), 1.47 (br s, 3H), 1.39 (s, 3H), 1.37 (s, 3H). 
13
C NMR (75 
MHz, CDCl3): δ 173.0, 114.9, 110.5, 81.1, 76.2, 75.9, 75.4, 26.9, 26.8, 26.0, 25.4. HRMS found 
= 281.0991 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
=281.0995. 
Synthesis of compound 10 
OH OH
OO
O
O
10  
To an ice cooled solution of 9 (1.99 g, 7.73 mmol) in MeOH (20 mL), NaBH4 (1.02 g, 27.0 
mmol) was added portion wise with stirring. The mixture was stirred at rt for 2 h. While cooling 
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the reaction mixture in an ice bath with vigorous stirring, 1.0 M AcOH solution in water was 
added drop wise to neutralize the mixture. After evaporation of solvents the residue was 
suspended in brine and extracted with EtOAc until TLC showed no product in the aqueous 
phase. The combined organic phase was dried over anhydrous Na2SO4 to obtain the crude 
product as colorless oil after evaporation of solvent. The crude product was purified using silica 
gel column (75% EtOAc in Hexane) to give compound 10 (1.619 g, 80%) as a colorless oil. Rf = 
0.25 (80% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 4.27-4.19 (m, 2H), 4.08-4.00 (m, 
2H), 3.83-3.73 (m, 4H), 3.10 (br s, 1H), 1.48 (s, 3H), 1.41 (s, 3H), 1.33 (s, 3H), 1.33 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3): δ 109.8, 108.7, 77.5, 76.2, 69.7, 66.0, 61.2, 27.1, 26.6, 25.4, 25.2. 
HRMS found = 285.1302 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
=285.1308. 
Synthesis of compound 11 
OH O
OO
CN
11
O
O
 
Compound 10 (0.600 g, 2.28 mmol) was dissolved in THF (15 mL) and the solution was, cooled 
to -75 
o
C and charged with NaH (0.105 g, 60% by wt in mineral oil, 4.37 mmol). The 
temperature was allowed to rise to 0
 
°C slowly and the mixture was allowed to stir at 0 °C for 90 
min. Added 5-bromovaleronitrile (0.320 g, 1.97 mmol) drop wise. The mixture was allowed to 
stir at rt for 2 d. The reaction was quenched with water and extracted with EtOAc. The organic 
phase was dried over anhydrous Na2SO4. The crude product was obtained as colorless oil after 
evaporation of solvent. The crude product was purified using flash silica gel column (70% 
EtOAc in Hexane) to obtain compound 11 (0.342 g, 62%) as colorless oil. Rf = 0.52 (80% EtOAc 
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in Hexane). 
1
H NMR (300 MHz, CDCl3): δ4.33-4.20 (m, 2H), 4.18-4.00 (m, 2H), 3.82-3.46 (m, 
5H), 2.76 (d, JH-H = 6.53, 1H), 2.38-2.33 (m, 2H), 1.73-1.70 (m, 4H), 1.48 (s, 3H), 1.42 (s, 3H), 
1.35 (s, 3H), 1.34 (s, 3H).
 13
C NMR (75 MHz, CDCl3): δ 119.6, 109.7, 108.9, 70.6, 69.9, 69.7, 
29.3, 28.5, 27.0, 26.7, 25.4, 25.1, 22.5, 17.1.  HRMS found = 366.1874 [M + Na]
 +,
 calcd for 
[C12H18O6+Na]
+ 
=366.1887. 
Synthesis of compound 12 
OH O
OO
COOH
12
O
O
 
To a solution of 11 (0.342 g, 0.995 mmol) in EtOH (16 mL) added 25 N NaOH (3.0 mL) and 
heated under was heated under reflux for 18 h. Reaction mixture was neutralized using 
concentrated HCl. Solvent was evaporated under reduced pressure to yield a white residue. The 
residue was washed with THF and the washings were filtered through a pad of celite. The crude 
product was obtained as colorless oil after evaporation of solvent. The crude product was 
purified using flash silica gel column (50% EtOAc in Hexane and then eluting the pure 
compound in MeOH) to obtain compound 12 (0.245, 87%) as a colorless oil. Rf = 0.21 (80% 
EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ4.24-4.20 (m, 2H), 4.02-3.97 (m, 2H), 3.79-
3.58 (m, 5H), 3.41-3.36 (m, 2H), 2.16 (br s, 2H), 1.53 (br s, 4H), 1.38 (s, 3H),  1.35 (s, 3H), 1.31 
(s, 3H), 1.30 (s, 3H) .
 13
C NMR (75 MHz, CDCl3): δ109.7, 109.4, 108.9, 71.8, 70.1, 69.2, 66.2, 
66.1, 35.6, 29.2, 27.0, 26.6, 25.6, 25.5, 25.2, 22.1. HRMS found = 385.1827 [M + Na]
 + 
calcd for 
[C12H18O6+Na] 
+ 
= 385.1832. 
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Synthesis of compound 13 
OH O
OHHO
COOH
13
HO
HO
 
Compound 12 (0.245 g, 0.678 mmol) was suspended in 10.0 mL of 1N HCl and refluxed for 1h. 
The reaction mixture was brought to rt and neutralized using 1N NaOH drop wise. Solvent was 
rotaevaporated to yield a white residue. The residue was washed with THF and the washings 
were filtered through a pad of celite. The filtrate was concentrated to yield 13 (quantitative) as a 
hygroscopic solid.
 1
H NMR (300 MHz, CDCl3): δ 3.94-3.29 (m, 10H), 2.21-2.19 (br s, 2H), 1.64 
(br s, 4H). 
13
C NMR (75 MHz, CDCl3): δ 182.3, 73.7, 72.7, 72.5, 72.1, 71.4, 71.0, 70.3, 69.2, 
63.0, 36.7, 29.2, 22.7. HRMS found = 305.1207 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 
305.1206. 
Conjugation of lysozyme with compound 13 
OH O
OHHO O
H
N
14
HO
HO
Lysozyme
 
Added 100 µL of 30 mg/mL solution of EDC and 6.6 µL of 30 mg/mL solution of NHS to 500 
µL of 1 mg/mL solution of compound 13 in MES buffer, at pH 6.0 and reacted for 15 min at rt. 
To the reaction mixture 0.7µl of mercaptoethanol was added to quench EDC, followed by 
addition of 500 µL of 1 mg/mL solution of lysozyme in MES buffer at pH 6.0, which was 
reacted for 2 h at rt. ESI-MS found = 14570.00[M] 
+
. The protein reaction was then dialysed in 
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PBS buffer, pH 7.4, to eliminate unreacted reagents. Degree of protein modification was 
analysed by ESI-MS. 
Synthesis of compound 17 
B
HO OH
NH
O
18
 
Compound 17 (0.100 g, 0.576 mmol) and NaHCO3 (0.193 g, 2.29 mmol) were dissolved in a 2:1 
vol/vol mixture of water and THF. To this solution acryloyl chloride (0.104 g, 1.15 mmol) was 
added at 0 °C, and stirred mixture for 1.5 h. Product was extracted with EtOAc. After 
evaporation of solvent the product was recrystallized with water to obtain compound 18 (0.020g, 
18%) as a white crystalline solid.
 1
H NMR (300 MHz, CDCl3): δ 7.87 (s, 1H), 7.71 (d, JH-H = 
7.05, 1H), 7.68-7.30 (br m, 2H), 6.48-6.31 (m, 2H), 5.77-5.73 (dd, JH-H= 9.52, JH-H= 9.46, 1H). 
HRMS found = 214.0649 [M + Na]
 +
, calcd for [C12H18O6+Na] 
+ 
= 214.0645. 
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Chapter 2 
Covalent Grafting of Proteins with Cyclodextrins Prevents Aggregation and Surface 
Adsorption and Increases Thermal Stability
*
  
 
Summary 
This chapter describes a general approach for modifying proteins with β-cyclodextrins (βCD) 
which prevents their aggregation and adsorption on surfaces, and increases their thermal 
stability. Using water-driven ligation, βCD is covalently tethered to the lysine residues of 
proteins via a squaramide linkage. The cyclodextrin-modified proteins exhibited significant 
reduction in aggregation, surface adsorption and an increase in thermal stability compared to 
unmodified proteins. These results are consistent with the hypothesis that molecules that can 
stabilize protein structure can also reduce protein aggregation and surface adsorption when 
grafted covalently to the surface of proteins. The ability of βCD to aid in protein folding will 
further be utilized to conjugate antibodies for targeted drug delivery and for increasing the 
stability of the antibody-conjugated drug. 
2.1 Background and Significance 
Aggregation and surface adsorption of protein-based biopharmaceuticals not only decreases 
the efficacy of a biopharmaceutical drug, but also causes undesired and sometimes fatal 
immunoresponse by the body. Both aggregation and surface adsorption of proteins are daunting 
problems faced by several industries, but are mostly studied as two separate problems. However, 
                                                          
*
 Reproduced in part with permission from Modification of Proteins with Cyclodextrins Prevents 
Aggregation and Surface Adsorption and Increases Thermal Stability, Deepali Prashar, DaWei 
Cui, Debjyoti Bandyopadhyay, and Yan-Yeung Luk* Langmuir, 2011, 27, 13091-13096. 
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in spite of their differences, both aggregation and surface adsorption of proteins involve some 
degree of protein denaturation. Covalent grafting of kosmotropic polyols such as β-cyclodextrins 
(βCD) on the surface of proteins can help preserve the folding stability of proteins and prevent 
protein denaturation. In this section of the dissertation, the chemistry for reducing both 
aggregation and surface adsorption and increasing thermal stability of proteins by modifying 
proteins with β-cyclodextrins is presented.  
2.1.1 Cyclodextrins can prevent protein aggregation 
Carbohydrates and their derivatives are another class of molecules known to stabilize protein 
folding, and in some cases prevent protein adsorption. In particular, cyclodextrin
52
 in solution 
has the ability to function as an artificial chaperone that refolds protein structures,
46-47, 53
 and 
inhibits aggregation. Cyclodextrin dimers have also been shown to disrupt protein aggregation.
54
 
These dimers cause the disruption of hydrophobic interactions between proteins, or between 
proteins and surfactants, strongly suggesting that the presence of cyclodextrin facilitates protein 
folding and refolding.  In addition to the hydrophobic patches on proteins that can cause protein 
association and aggregation, 
55-56
  chaotropic additives can also promote protein denaturation and 
aggregation. Covalent grafting of cyclodextrins onto proteins offers an entirely new approach for 
preventing protein adsorption and aggregation and enhancing their thermal stability.  
2.1.2 Cyclodextrins versus poly(ethylene glycol) for increasing protein stability 
Unlike oligo(ethylene glycol) (OEG) or poly(ethylene glycol) (PEG), cyclodextrins have well-
defined molecular weights and rigid conformations. Cyclodextrins have both hydrogen bond 
acceptors and donors, whereas PEG only possesses hydrogen bond acceptors. Thus, the solvation 
of βCD and PEG in water will be different. When grafted on proteins, βCD can exhibit a fixed 
conformation with limited orientational variations, whereas PEG can exhibit a large ensemble of 
53 
 
 
 
conformations and orientational variations. These differences suggest that both the enthalpy and 
entropy for aggregation and surface adsorption are different for βCD-grafted and PEG-grafted 
proteins.  The mechanisms involved in reducing both protein aggregation and surface adsorption 
for βCD-grafted and PEG-grafted proteins will also be different. 
 Recent studies suggest that while kosmotropic anions stabilize protein structures by direct 
interactions,
9, 12-13, 16
 the effect of nonionic organic osmolytes on proteins is likely indirect.
9
 
Particularly for sugar molecules that stabilize protein structures,
57
 by exerting a long range effect 
on solvent water, the hydrogen bonding associated with molecular solvation is likely multivalent 
in nature. For instance, sucrose gradients commonly used for purification of biomolecules, 
consists of visible layers of different density that can be easily prepared and do not readily 
become a homogeneous solution.
58
 For this reason, I believe that the multiple hydroxyl groups in 
cyclodextrin can hydrogen bond with water molecules and can act as a template to build a 
structured solvation shell that contributes to two plausible mechanisms for preventing 
aggregation and surface adsorption. First, folding stability is increased by grafting βCD on 
protein surfaces, thus reducing the denaturation-initiated aggregation and surface 
adsorption. Second, βCD creates less dynamic hydration shells on proteins, which prevent 
proteins moving into close contact with each other. 
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Figure 2.1 A schematic representation demonstrating the ability of the multiple hydroxyl groups 
of β-cyclodextrin to generate a structured solvation shell by hydrogen bonding with surrounding 
water molecules. 
 It is also possible that the βCD groups grafted covalently on the surface of proteins form 
intramolecular inclusion complexes with nearby hydrophobic residues on the same protein.
59
 
However, such binding may also induce intermolecular binding that would lead to aggregation. 
The mechanism of this intramolecular inclusion does not exclude the model presented in this 
chapter. Both can be effective under different conditions.  
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2.1.3 Different methods of protein glycosylation 
Glycosylation of proteins has been used to enhance the solubility, increase stability and 
activity of proteins.
60-63
A number of methods exist for conjugating monosaccharides or 
oligosaccharides to proteins and peptides.
64
 One approach is chemical modification of reactive 
amino acid residues in proteins and peptides with sugar derivatives. These methods include 
formation of acetimidine,
65
 glycosylmaleimides,
66
 diazo,
67
 thiourea,
68-69
 amide
62, 70-72
 and 
disulfide bond formation.
73
 Lemieux and co-workers have reported that bovine serum albumin 
can be chemically glycosylated via amide bonds, to generate semisynthetic antigens for raising 
carbohydrate specific antibodies.
70
 Hindsgaul and coworkers reported squarate-based chemical 
modification, to couple oligosaccharide amines to proteins using diethyl squarate (Scheme 2.1).
74
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Scheme 2.1 Different methods of protein glycosylation 
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Another approach for glycosylating proteins and peptides involves a combination of site-
directed mutagenesis and chemical modification.
75-76
 Ullman and co-workers have introduced 
cysteine residues into proteins, to facilitate the coupling of the thiol group of cysteine 
specifically with glycomethanethiosulfonate (glycoMTS) reagents via disulfide linkages.
77
 
Copper catalyzed click reactions between alkyne modified proteins and sugar azides have been 
used by Carell and co-workers for glycosylation of proteins.
78
 Bertozzi and co-workers 
demonstrated that enzymatic methods can be used to introduce aldehyde groups at selective 
positions of peptides. These aldehyde groups were further reacted with aminoglycosides to 
produce glycosylate peptides via oxime bonds.
79
 While significant advances have been made in 
bioconjugation in recent years, 
80-83
 modification of proteins with cyclodextrins, particularly with 
a stable and well-characterized bond identity remains a challenge.  
In this work, I report the direct covalent modification of lysine residues of proteins with β-
cyclodextrin (βCD), using water-driven ligation with activated amino squarate reagents36, 84-87. 
The lysine residues of lysozyme and RNase A were covalently modified with βCD with the aim 
of preventing protein aggregation and surface adsorption and to promote thermal stability.  
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Table 2.1 Amino acid sequence of lyszozyme and RNase A. Lysine (K) is indicated in red font 
and the lysine residues in the active site are highlighted in blue font. 
Source: NCBI Sequence Viewer 
http://www.ncbi.nlm.nih.gov/protein  
 
Table 2.1 gives the amino acid sequence of lysozyme and RNase A. Lysozyme and RNase A 
have six and ten lysine residues respectively. Although lysozyme does not have any lysine 
residues in its active site, one lysine residue is present in the active site of RNase A. If the lysine 
residue in the active site of the proteins is covalently modified with βCD, the activity of the 
protein may be lost. Furthermore, the large βCD group, which has an outer diameter of 1.54 nm, 
might itself block the active site of the proteins and may lead to reduced protein activity.  
2.2 Results and Discussion 
Amino squarates are stable in water, but have unique reactivity for substitution that is driven 
by the hydrogen bonding ability of water.
36
 The unique stability and reactivity of squarate 
reagents in water provides an opportunity to modify proteins effectively with βCD-based amino 
squarate reagents. 
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2.2.1 Synthesis of βCD-derivatized amino squarate reagents 
Scheme 2.3 shows the optimized synthesis of βCD amino squarate reagents 6, 7 and 8. Briefly, 
compounds 1,
85
 4
36
 and mono-6-amino-6-deoxy-β-cyclodextrin, 588-89 were synthesized using 
literature-reported procedures. Compounds 2 and 3 were obtained by coupling 1 with 3, 5-
difluorophenol and 4-fluorophenol, respectively, in the presence of triethyl amine (TEA). 
Compounds 6, 7 and 8 were obtained by mixing 5 with compound 2, 3 or 4, respectively, in 
water with minimal amounts of  N,N’-dimethylformamide (DMF) and acetone. 
Scheme 2.2 Synthesis of βCD-derivatized amino squarate reagents 
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βCD amino squarates 6, 7 and 8 (Scheme 2.2) were synthesized to covalently modify the lysine 
residues in the proteins lysozyme and RNase A with βCD. The introduction of an electron 
withdrawing fluorine group on the phenyl moiety in the βCD amino squarate reagent may cause 
the lysine residues of proteins to displace the fluorinated phenoxy substituent more efficiently 
than a phenoxy substituent. After synthesizing the compounds, the degree of modification of the 
lysine residues in lysozyme (lysozyme-(βCD)n, n can range from 1 to 6) with reagents 6, 7 and 8 
at 5 h, 10 h, 24 h, 48 h and 72 h was studied using matrix assisted laser desorption ionization 
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time of flight (MALDI-TOF) mass spectrometry. It was observed that all three amino squarate 
reagents modified the same number of lysine residues, but the intensity of the mass peaks in the 
MALDI spectrum corresponding to each degree of modifications ((lysozyme-(βCD)1, (lysozyme-
(βCD)2, (lysozyme-(βCD)3 etc.) was different. After 5 h, two lysine residues of lysozyme were 
modified with βCD using 6, 7 and 8; however the intensity of peaks corresponding to different 
degree of modifications using reagent 6 was higher than that by using reagents 7 or 8. After 10 h, 
number of lysine residues modified with 6, 7 and 8 increased to three, but the intensity of the 
mass peaks corresponding to different degree of modifications were highest for 6, followed by 7 
and 8.  Prolonged reaction time (72 h) increased the degree of modification of lysine residues to 
four, with the intensity of peaks corresponding to different degree of modifications being similar 
for all three compounds 6, 7, and 8.  
2.2.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and MALDI-TOF 
confirms the degrees of modification in lysozyme with βCD 
To further characterize the products of lysozyme modification with βCD, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted on lysozyme modified 
with 6, 7 and 8. Separate bands corresponding to one, two and three lysine residues modified 
with βCD, were observed on the SDS-gel (Figure 2.2). This observation is consistent with the 
results from MALDI-TOF analysis, where multiple βCD modifications were observed in the 
protein lysozyme.  
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Figure 2.2 SDS-PAGE showing separate bands corresponding to one and two modifications of 
lysozyme (0.05 mg/mL) with βCD using compounds 6, 7 and 8. Lane A is lysozyme; lane B, C 
and D are for lysozyme modified with 8, 7 and 6 respectively. Inset above shows SDS-PAGE 
with high concentration of modified lysozyme (0.5 mg/mL) showing separate bands 
corresponding to one, two and three modifications with βCD. 
2.2.3 Modification of lyoszyme using NHS/EDC coupling 
The modification of lysozyme with βCD using N-hydroxy succinimide/1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (NHS/EDC) or N,N'-
dicyclohexylcarbodiimide (DCC) chemistry was also attempted. Compound 12 was synthesized 
to conjugate βCD to the lysine residues in lysozyme using NHS coupling chemistry. The 
synthesis of compound 12 is shown in Scheme 2.3. Briefly, compound 9 was activated with 
NHS/DCC to give the ester 10. Compound 10 was further treated with the amine 5
88-89
 to afford 
the amide 11. Base hydrolysis of compound 11 gave the acid 12. Treatment of lysozyme with 
activated 12 (prepared in situ with EDC and NHS) should have afforded lysozyme-(βCD)n. 
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However, MALDI-TOF analysis on the dialysed sample for lysozyme modification with 12 
indicated absence of any modification. It is possible that lysine residues could not be modified 
with βCD due to the hydrolytic instability of the amide bond linking βCD to the lysine residues 
of proteins. Cyclodextrins presumably can also catalyze hydrolysis of ester bonds.
90
 Hence, 
modification of proteins with βCD using the squarate chemistry is a better method compared to 
NHS/EDC chemistry, due to the hydrolytic stability of the squaramide linkage. 
Scheme 2.3 Modification of lysozyme using NHS/EDC coupling 
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2.2.4 Prevention of protein aggregation 
Lysozyme and RNase A are the most studied model proteins and their aggregation propensity 
has been widely reported.
91-97
 The aggregation process largely depends on pH, temperature and 
protein concentration. Earlier reports using equilibrium sedimentation have shown that 1 mM of 
hen egg white lysozyme forms dimers in the pH range 5–9 and higher oligomers at pH 10–11.95-
96
 Hen egg white lysozyme has also been  reported to form fibrils at acidic pH and elevated 
temperatures.
98
 Aggregation of lysozyme at micro molar concentrations has been shown to be 
initiated at an alkaline pH of 12.2.
92
 Dimers of RNase A have been reported to form at 37 °C and 
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65 °C at pH 6.5.
93, 97
 Ribonuclease A (RNase A) has also been shown to form aggregates when 
stored in the freeze-dried form at elevated temperatures.
94
 
2.2.5 Dialysis in water aggregates only unmodified proteins 
After the reaction of lysozyme with the βCD-amino squarate reagent 6, the unreacted reagents 
were removed by dialysis in phosphate buffered saline (PBS), pH 7.4. Interestingly, further 
dialysis of the samples in deionized water instead of in buffer, followed by filtration of the 
protein solution through a 0.2 µm syringe filter, resulted in a significant reduction in the amount 
of unmodified protein. MALDI-TOF spectra showed that up to four lysine residues in lysozyme 
were modified with βCD (Figure 2.3) using compound 6. The MALDI-TOF spectrum of protein 
samples dialyzed overnight in deionized water showed mass peaks corresponding mainly to the 
modified protein. RNase A was also modified with βCD using compound 6. Similar degree of 
modification was obtained with RNase A (Figure 2.4). MALDI- TOF analysis showed only 
small amount of unmodified RNase A relative to the βCD modified RNase A. Furthermore, 
MALDI-TOF analysis on samples of modified RNase A dialysed in deionized water indicated 
the presence of small amount of unmodified RNase A, while the peaks of βCD modified RNase 
could still be observed. The effect of ionic strength on protein stability depends on the nature of 
the protein.
91, 99
 These results suggest that unmodified lysozyme and RNase A form aggregates 
due to low ionic strength of deionized water. I believe that the modification of protein with βCD 
stabilizes the folded structure of the protein and prevents denaturation and aggregation, thus only 
the unmodified proteins formed aggregates during the stress of dialysis. 
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Figure 2.3 MALDI-TOF spectra for lysozyme-(βCD)n (A) before and (B) after dialysis in 
deionized water.   
 
 
 
Figure 2.4 (A) MALDI-TOF spectra for RNase A-(βCD)n (B) MALDI-TOF spectra for RNase 
A-(βCD)n after dialysis in water. 
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2.2.6 Dynamic light scattering on lysozyme-(βCD)n  and aged lysozyme for protein size 
determination 
Dynamic light scattering (DLS) is a technique used to measure the size distribution profile of 
small particles in suspension or polymers in solution. When the light source hits the particles, 
fluctuation in the scattering intensity is observed which the instrument detects. 
Dynamic light scattering was conducted to measure the aggregation behavior of βCD-modified 
proteins and unmodified proteins, which were aged under same reaction conditions and stress 
factors including aging, freeze-drying, and dialysis. I discovered that dialysis in pure water was 
the major cause for complete aggregation of unmodified lysozyme, but βCD-modified proteins 
remained monomeric under the same conditions. After dialysis in pure water lysozyme-(βCD)n 
showed only monomeric proteins with a hydrodynamic diameter of about 3.8 nm in the number 
and volume distributions (Figure 2.5A). Under the same conditions of dialysis in pure water, the 
entire sample of unmodified lysozyme formed aggregates, with a hydrodynamic diameter about 
698 nm (Figure 2.5B).  
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Figure 2.5  Number (A and B) and volume (C and D) distribution of DLS showing two replicates 
each for 1 mg/mL of lysozyme-(βCD)n and lysozyme in PBS buffer pH 7.4 at 25 °C. Volume 
distribution showed only monomeric proteins for lysozyme A-(βCD)n (A) and only aggregates 
for aged lysozyme (B). Number distribution showed only monomeric proteins for lysozyme A-
(βCD)n (C), and only aggregates for aged lysozyme (D). The aging conditions are: 1 mL solution 
of lysozyme (1 mg/mL) was prepared in 1× PBS buffer pH 8.2. The protein solution was then 
placed in a 28 ºC incubator shaker for 72 h. The sample was then dialyzed in water overnight and 
then freeze dried to obtain a white solid. 
 
The same results were observed for RNase A, where RNase A-(βCD)n showed only 
monomeric proteins in the number and volume distributions whereas, RNase A under the same 
conditions showed only aggregates in the number and volume distribution (Figure 2.6). 
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Figure 2.6 Volume (A and B) and Number (C and D) distribution of DLS showing two 
replicates for 1 mg/mL of RNase A-(βCD)n and aged RNase A  in 1× PBS buffer pH 7.4 at 25 
°C. Volume distribution showed only monomeric proteins for RNase A-(βCD)n (A) and only 
aggregates for aged RNase A (B). Number distribution showed only monomeric proteins for 
RNase A-(βCD)n (C), and only aggregates for aged RNase A (D).The aging conditions are: 1 mL 
solution of RNase A (1 mg/mL) was prepared in 1× PBS buffer pH 8.2. The protein solution was 
then placed in a 28 ºC incubator shaker for 72 h. The sample was then dialyzed in water 
overnight and then freeze dried to obtain a white solid. 
2.2.7 Thermo-induced aggregation of unmodified lysozyme and lysozyme-(βCD)n  using dynamic 
light scattering (DLS). 
Past studies have shown that trypsin modified with α, β and γ CD are stable when heated to 70 
ºC, whereas native trypsin was totally inactivated at 60 ºC.
98, 100 
 During thermo-induced 
aggregation studies of unmodified lysozyme and lysozyme-(βCD)n  using DLS, it was  observed 
that heating unmodified lysozyme (0.5 mg/mL in 1 × PBS buffer at pH 7.4) at 67 ºC for 25 min 
resulted in complete aggregation, whereas only monomeric proteins were observed when 
lysozyme-(βCD)n  was treated under the same conditions. While aggregates begin to appear after 
heating lysozyme-(βCD)n at 77 °C for 25 min, the sample contained mostly monomers. 
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Complete aggregation of lysozyme-(βCD)n was observed only when the same sample was heated 
at 87 °C for 25 min (Figure 2.7). 
 
 
Figure 2.7 Number distribution of DLS of unmodified lysozyme and lysozyme-(βCD)n (0.5 
mg/mL in 1 × PBS, pH 7.4). Number distribution for unmodified lysozyme kept at (A) 57 ºC,  
(B) at 67 ºC for 25 min and for lysozyme-(βCD)n (C) at 67 ºC and (D) at 87 ºC for 25 min. 
2.2.8 Surface adsorption of lysozyme-(βCD)n and native lysozyme using surface plasmon 
resonance (SPR). 
I believe that aggregation and surface adsorption of proteins share some common mechanism. 
Thus, modification that results in preventing aggregation should also reduce or prevent surface 
adsorption. Surface plasmon resonance (SPR) is a widely used technique to measure the amount 
of specifically or non-specifically adsorbed protein on the surface of gold.
101-102
 Surface 
plasmons are surface electromagnetic waves, which run parallel to the metal air/solution 
interface. These waves are very sensitive to the changes occurring at the interface, such as the 
adsorption of molecules or biomolecules on the metal surface. When proteins adsorb on the 
metal surface a decrease in the intensity of the reflected light is observed which the SPR 
instrument measures.  
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To measure the effect of βCD modification on surface adsorption of proteins, I used SPR to 
directly monitor the adsorption of modified and unmodified proteins on gold surfaces of 1 mm 
diameter spots (on a 16-spot microarray). The experiment was performed by first flowing 
phosphate buffered saline (1 × PBS,  pH 7.42) through the flow cell followed by flowing 0.5 
mg/mL solutions of lysozyme-(βCD)n and lysozyme in separate channels in the same buffer and 
then finally flowing PBS again (Figure 2.8A). The amount of protein which adsorbs irreversibly 
on gold was estimated by comparing the SPR intensity in pixel intensity units before and after 
the gold surface was exposed to the protein solutions. From the SPR data, the pixel intensity 
units (PIUs) was calculated by taking the average of all runs performed for lysozyme and 
lysozyme-(βCD)n adsorptions. By assuming the adsorption exhibited by lysozyme to be 100%, 
the % monolayer (% ML) for lysozyme-(βCD)n was calculated to be 6.75 ± 2.4% using the 
formula % ML= {ΔPIU [(lysozyme-(βCD)n] / ΔPIU (lysozyme)} ×100. Hence, it can be said that the 
lysozyme adsorption was reduced by ~93% after modification of lysozyme with βCD. This result 
proves lysozyme-(βCD)n is stable against adsorption on gold surfaces. For RNase A, %ML for 
adsorbed RNase A-(βCD)n on gold surface was found to be 21.26 ± 2.62% over eight replicates, 
corresponding to a reduction of adsorption by  80% (Figure 2.8 B). I noted that whereas the 
adsorption of lysozyme-(βCD)n appeared to have reached equilibrium, adsorption of RNase A 
did not. This result suggests that, at least for RNase A, modification of proteins with βCD can 
reduce only the rate of protein adsorption. 
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Figure 2.8 Four replicates of surface plasmon resonance (SPR) of the adsorption of (A) 
lysozyme and lysozyme-(βCD)n, (B) RNase A and RNase A-(βCD)n, (0.5 mg/mL of protein in 
1× PBS, pH 7.4). The SPR intensity (pixels) is plotted against time (seconds) as protein solutions 
are flowed over a SPR micro array. 
2.2.9 Measuring activity of lysozyme-(βCD)n and native lysozyme using turbidimetric method 
An enzymatic assay was used to determine the activity of lysozyme-(βCD)n and native 
lysozyme.
103-104
 The assay involves the use of Micrococcus lysodeikticus bacterial cells as a 
substrate for the enzyme lysozyme, where the enzyme is responsible for degrading the 
bacterium’s cell wall. A suspension of the M. lysodeikticus cells is mixed with a small amount of 
the protein. As the enzyme acts on the suspension of bacterial cells, the turbidity of the 
suspension and therefore the absorbance of the sample decreases. The rate of decrease in the 
turbidity is a relative measure of the activity of lysozyme present in the sample. The more the 
amount of lysozyme present in the sample, the faster is the reaction and the decrease in 
absorbance. The activity of lysozyme-(βCD)n was found to be lower than that of native lysozyme 
(Figure 2.9).  
The turbidimetric method indicated that the activity of lysozyme-(βCD)n  had reduced 
significantly compared to the native lysozyme. However, it is important to note that the activity 
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in general depends on individual proteins. Since a mixture of proteins with different degree of 
modifications is being examined, some modification may be of lower activity than others. The 
reduced activity of lysozyme-(βCD)n  could also be  due to the blocking of  the lysozyme active 
site by the large βCD molecules. Masuda and co-workers have reported that if the positive 
charge on the lysine residues in lysozyme is modified, the lytic activity of lysozyme towards M. 
lysodeikticus tends to decrease.
105
 Hence, the blocking of the positive charges on the lysines by 
the βCD sqaramide may also be responsible for the reduced activity of lysozyme-(βCD)n. 
 
 
Figure 2.9 Decrease in optical density with time of suspensions of Micrococcus Lysodeikticus 
following addition of lysozyme and lysozyme-(βCD)n. The absorbance of the sample was 
measured at 450 nm. 
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2.2.10 Purification of lysozyme-(βCD)n. by protein crystallization 
The science for aiding the crystallization of proteins (lysozyme), using a class of 
nonamphiphillic organic molecules that can form liquid crystal phases in water is reported in the 
literature and has been developed in Professor Luk’s laboratory.106 Based on the above 
knowledge 5’ disodium cromoglycate (5’ DSCG) and sodium chloride (NaCl) was used for 
crystallizing lysozyme and lysozyme-(βCD)n. Lysozyme and lysozyme-(βCD)n were crystallized 
via vapor diffusion using the hanging drop method.
107
 The crystallization of lysozyme and 
lysozyme-(βCD)n was tried using sodium chloride (958 mM) and 5’DSCG (5.47 mM). 
Tetragonal shaped lysozyme crystals were observed in the drops containing 5’DSCG and NaCl 
(Figure 2.10). However lysozyme-(βCD)n  crystals were not observed in the drops containing 
both 5’DSCG and NaCl. Crystallization of proteins starts with the formation of stable nuclei in a 
supersaturated protein sample. Formation of the stable nuclei is followed by coming together of 
more protein molecules to generate a macromolecular network. This network consists of 
channels, which are surrounded by “water bound” protein and possibly ions of the precipitant 
salt. The “bound water” forms an ordered hydration shell around the protein and situates itself 
adjacent to the protein molecules in the crystal lattice. This bound water participates in the 
extended hydrogen bonding that mediates indirect interaction with the protein molecules.
108-109
 
Lysozyme-(βCD)n  failed to show any crystal formation may be because a stable nuclei could not 
form due to the presence of the large βCD groups on the surface of the protein. Even if a stable 
nuclei can form in case of lysozyme-(βCD)n, the large βCD groups on the surface of the protein 
can possibly  inhibit the protein molecules from coming together to form a network of 
macromolecules for inducing crystallization. This further supports the hypothesis that covalent 
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grafting on proteins with βCD prevents proteins molecules from coming together to form 
assemblies or possibly aggregates. 
 
Figure 2.10 Lysozyme crystals induced by (A) 5’DSCG (figure adapted from reference 106) and 
(B) NaCl additives in hanging droplets. Lysozyme-(βCD)n crystals  induced by (C) 5’DSCG and 
(D) NaCl additives in hanging droplets. Scale bar = 76 µm. 
 
2.2.11 Modification of Bovine Serum Albumin (BSA) with βCD 
Modification of bovine serum albumin (BSA) with βCD using compound 6 was also 
conducted. Bovine serum albumin (BSA) is a large protein with 583 amino acids and close to 50 
lysine residues. Even though BSA has fifty lysine residues, MALDI-TOF analysis indicated that 
only one lysine residue in BSA was modified with compound 6 (Figure 2.11).  
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Figure 2.11 MALDI-TOF spectra for BSA-(βCD)n. 
This could be due to less number of lysine residues being present on the surface of the protein 
BSA. The removal of unmodified BSA from BSA-(βCD)n was tried by dialyzing the sample 
containing the mixture of modified and unmodified BSA in deionized water. However, MALDI 
TOF analysis indicated that dialysis in deionized water could not remove the unmodified BSA 
completely. Dynamic light scattering was conducted on the mixture containing modified and 
unmodified BSA (Figure 2.12). The number distribution indicated that the mixture of proteins 
was monomeric and the observed hydrodynamic diameter was consistent with the reported 
hydrodynamic diameter of ~7.0 nm for native BSA. 
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Figure 2.12 Number distribution of DLS of BSA-(βCD)n (1.0 mg/mL) in 1 × PBS, pH 7.4) at 
25°C. 
Surface plasmon resonance was also conducted to measure the surface adsorption of the 
mixture of BSA-(βCD)n and unmodified BSA versus unmodified BSA. Relative to the 
unmodified BSA, %ML for the mixture of BSA-(βCD)n and unmodified BSA was found to be 
80.05 ± 6.5% (Figure 2.13). These results suggest that modification of BSA with βCD could only 
reduce surface adsorption by ~20% and that higher reduction in surface adsorption might be 
possible on achieving higher degree of modification of lysine residues with βCD.  
 
 
 
 
 
76 
 
 
 
 
Figure 2.13 Four replicates of surface plasmon resonance (SPR) of the adsorption of BSA and 
mixture of unmodified BSA and BSA-(βCD)n, (0.5 mg/mL of protein in 1× PBS, pH 7.4). The 
SPR intensity (pixels) is plotted against (seconds) as protein solution is flowed over a SPR micro 
array. 
2.2.12 Covalent modification of aniline grafted proteins with amino squarate based reagents 
Francis and coworkers have developed an efficient protein modification reaction that couples 
new functionality to anilines under conditions mild enough to preserve the function of most 
biomolecules.
110
 Luk and coworkers have synthesized heterocyclic amino squarate based 
compounds such as 13 (Scheme 2.4), to covalently modify aniline-grafted proteins under neutral 
conditions in aqueous solutions. N-hydroxysuccinimide (NHS) ester derivatives cannot be used 
for this covalent modification strategy since anilines do not react with NHS esters but only with 
squarates. Furthermore, while water does not readily hydrolyze squarates, it can easily hydrolyze 
N-hydroxysuccinimide (NHS) esters.   
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Scheme 2.4 Heterocyclic amino squarate based compounds for protein modification 
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Motivated by the science developed by Francis and coworkers, lysine residues of proteins 
modified covalently with anilines were further conjugated with either cyclic amino squarates 
having pendant pyridinium group (13)
 or with βCD amino squarate (6) (Scheme 2.5). The alkyl 
group (-R) of the pyridinium moiety in the cyclic amino squarates (13) can act as a handle for 
conjugating ligands or small molecule based drugs, while the βCD conjugated to the squarate can 
serve as a host to carry and deliver small molecule drugs. 
Scheme 2.5 Sequential modification of proteins with NHS derivatized aniline (14) and 
compound 13
†
 
 
 
 
 
 
                                                          
†
 Compounds 13 and 14 were synthesized by Dr DaWei Cui in Professor Y-Y Luk’s lab. 
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Proteins lysozyme and RNase were first grafted with aniline groups by modifying the lysine 
residues with NHS ester derivatized aniline (14) (Scheme 2.5, Step I). The aniline-grafted 
proteins were further conjugated with compound 13 (Scheme 2.5 Step II). Proteins (58 µM 
lysozyme and 60 µM RNase A) in 10 mM of PBS buffer at pH 8.2 were treated with 100 
equivalents of compound 14,
111
  for about 5 h. The aqueous solutions of the reaction mixture 
were dialyzed in 1× PBS buffer, pH 6.0 to remove small molecule reagents. MALDI-TOF 
revealed that up to five lysine residues on lysozyme and up to eight lysine residues on RNase A 
were modified with aniline derivatives (Figure 2.9). The aniline modified proteins were further 
mixed with 50 equivalents of a cyclic amino squarate, 13 (in 200 µL of PBS, pH 6.0) for 16 h. 
For proteins presenting multiple copies of anilines, a few unmodified anilines were also present. 
All the reactions of the aniline modified proteins with compound 13 were conducted at pH 6.0 to 
keep the lysine residues in the proteins protonated and to ensure that the reaction happens only 
with the anilines bound covalently to the proteins. MALDI-TOF analysis showed mass adducts 
exhibiting high level of modification of multiple aniline groups with 13 for both RNase A and 
lysozyme (Figure 2.14). 
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Figure 2.14 MALDI-TOF spectra for (A) lysozyme modified with compound 14 and (B) aniline 
modified lysozyme further modified with compound 13 (C) RNase A modified with compound 
14 and (D) aniline modified RNase A further modified with compound 13.  
Before reacting aniline grafted proteins with compound 6, the reactivity of aniline with 6 in 
water was first tested and studied by UV-Vis and MALDI-TOF (Scheme 2.6). When aniline 
reacts with compound 6, compound 15 is formed as product and compound 16 is formed as a 
byproduct in the reaction. The reaction was monitored by measuring the UV absorption every 5 
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min for the first 30 min and then every hour for the next 7 h. A small change was observed in the 
UV-Vis absorption spectrum over 7 h, suggesting that the rate of reaction was very slow. 
MALDI-TOF confirmed that there was indeed product formation after reaction of aniline with 6 
in water (Figure 2.15). 
Scheme 2.6 Reaction of aniline with compound 6 
 
 
 
 
Figure 2.15 (A) Absorption spectra for the ligation of aniline with compound 6 in water at 
increment of 1 h from 1 to 7 h. Reaction conditions: Aniline (50 µM in H2O), 6 (1eq), rt (B) 
MALDI-TOF spectra for the reaction mixture of aniline with compound 6 in water after 24 h. 
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Table 2.2 lists the different conditions tried for the sequential conjugation of proteins lysozyme 
or RNaseA with compound 14, followed by compound 6. The different degrees of modifications 
for the aniline grafted proteins were characterized by MALDI-TOF. When the aniline activated 
lysozyme was modified with 6 at pH 8.2, up to three lysine residues got modified with βCD. 
However, at pH 8.2 it is not possible to determine whether the reaction is happening at the free 
lysines residues or with anilines bound covalently to the protein.  Hence, all the reactions for the 
aniline activated proteins with compound 6 were conducted at pH 6.0 to keep the lysine reisdues 
on the protein protonated. When lysozyme was directly modified with compound 6 at pH 6.0, 
only negligible modification of the lysine residue with βCD was observed even after 72 h. When 
aniline activated lysozyme and RNase A were modified with compound 6, up to three (Figure 
2.16) and five lysine residues were modified with βCD respectively after 72 h.  
Table 2.2 Different conditions tried for sequential conjugation of lysozyme and RNase A with 
compound 14 followed by modification with compound 6. 
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Figure 2.16 MALDI-TOF spectra for lysozyme (46.67 µM) modified with aniline and further 
modified with compound 6. Modification of lysozyme-aniline with 6 was run at pH 6.04 for 72 
h. 
The covalent modification of aniline grafted proteins by oxidative method,
110
 appears to be 
slower than using amino squarate based  reagents. While reaction with compound 13 requires 5 
to 16 h, reaction with compound 6 requires 72 h. This strategy of incorporation of anilines into 
proteins and peptides provides a powerful solution to the problem of inability to achieve protein 
modification in a single location due to the absence of a reactive residue. Furthermore, this 
strategy can be used for site specific incorporation of poly(ethylene glycol) or other functional 
groups for protein-based drugs. 
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2.3 Conclusions and Perspectives 
A water-driven chemistry that modifies proteins efficiently with cyclodextrin has been 
developed. Cyclodextrin-modified proteins exhibited significant reduction in aggregation and 
surface adsorption and increase in thermal stability as compared to unmodified proteins. These 
results are consistent with a unifying hypothesis that grafting proteins with molecules that 
stabilize protein structure can also reduce protein aggregation and surface adsorption. This 
chemistry also helps us to understand and validates future studies on protein stability and protein 
engineering at selected sites for design properties and activities. Furthermore, cyclodextrin can 
form noncovalent host-guest inclusion complexes with hydrophobic groups in water. Tethering 
the hydrophobic groups with small molecules or drugs enables combined drug therapeutics as 
well as targeted drug delivery. These studies along with artificial glycosylation and the 
mechanistic studies of aggregation and surface adsorption of modified proteins are the subjects 
of ongoing research in Professor Luk’s laboratory. 
 
2.4 Experimental Section 
Materials and Methods 
Chemicals. Chicken egg white lysozyme (catalog number L6876) and RNase A (catalog 
number R6513) were obtained from Sigma Chemical Company (St. Louis, MO) and were used 
without further purification. Sinapinic acid was obtained from ProteoChem (Denver, CO). 
Phosphate buffered saline, 1× PBS (2.7 mM potassium chloride, 137 mM sodium chloride, 8 
mM sodium phosphate dibasic, 1.48 mM potassium phosphate monobasic) was used for all 
protein reactions unless mentioned (pH of the prepared buffers was adjusted using 1N HCl and 
1N NaOH). Cameo 3A Syringe Filters, Acetate 0.22 Micron, 3 mm, were obtained from GE 
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Water & Process Technologies (Trevose, PA). Disodium cromoglycate (5 ′DSCG ) was 
purchased from MP Biomedicals (Solon , OH). All other chemicals were obtained from Aldrich 
Chemicals (Milwaukee, WI). Deionized water used for preparing all buffers and solutions had 
resistivity of 18 MΩ cm (Millipore, Billerica, MA).  
Modification of lysozyme with βCD 
Compound 6 (4.68 mg, 50 eq.) was added to a solution of lysozyme/RNase A (1 mg/mL) 
prepared in 1× PBS pH 8.2 (reaction buffer).  The reaction mixture was stirred in a 28 ºC 
incubator shaker for 72 h. The reaction mixture was dialyzed in 250 mL 1× PBS, pH 7.4. 
MALDI-TOF was conducted on the sample to see the number of modification on the protein. 
The modified protein sample was freeze dried to obtain a light yellow solid.  
Dialysis 
 The protein samples were dialyzed in 1× PBS and/or in water (dialysis media), using Slide-A-
Lyzer Dialysis Cassettes 7K MWCO purchased from Thermo Scientific (Rockford, IL). Before 
use, the Slide-A-Lyzer Dialysis Cassette was hydrated in the dialysis media for 5 min. Sample 
was injected in the cassette and placed in 250 mL of dialysis media to get rid of unreacted 
compound 6. The 1× PBS was changed twice every 2 h for the first 6 h and then left overnight. 
The same reaction mixture was further dialyzed in a new dialysis bag in 250 mL of deionized 
water to promote aggregation of unreacted protein. The deionized water was changed twice 
every 2 h and then left overnight. Reaction mixture was then passed through a syringe filter (0.22 
µm) to eliminate aggregated protein. 
 
 
 
85 
 
 
 
Aging of Unmodified lysozyme/RNase A 
A solution of lysozyme/RNase A (1 mg/mL) was prepared in 1× PBS buffer pH 8.2. The 
protein solution was then placed in a 28 ºC incubator shaker for 72 h. The sample was then 
dialyzed in water overnight and then freeze-dried to obtain a white solid. This aging condition 
was the same as the reaction conditions for modifying proteins with βCD, except that compound 
6, 7 or 8 were not added. The sample was not passed through the syringe filter. 
Matrix Assisted Laser Desorption Ionization (MALDI)  
A saturated solution of sinapinic acid (matrix) was prepared in a mixture acetonitrile and 
aqueous 0.1% TFA (1:2). Protein solution was mixed with aqueous 0.1% TFA solution and 
sinapinic acid solution in a 1:1:1 ratio and spotted on a MTP 384 target ground steel plate 
(Bruker Daltonics, Billerica, MA). Mass spectra were obtained on a MALDI TOF/TOF Mass 
spectrometer, Bruker AutoFlex III instrument (Bruker Daltonics, Billerica, MA). Protein mass 
was measured using a positive ion linear mode.  
Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) experiment was performed on MALVERN zetasizer 
nanoseries (MALVERN Instruments Ltd. Worcestershire, UK) at a scattering angle of 173°. 
Protein solution (1 mg/mL) of lysozyme-(βCD)n /RNase A-(βCD)n and aged lysozyme/RNase A 
in 1× PBS buffer pH 7.4 at 25 °C was used for all DLS experiments. 
Surface Plasmon Resonance (SPR) 
 All surface plasmon resonance (SPR) experiments were performed on a SPRimager
®
II Array 
System (GWC Technologies, Madison, WI). Protein solution (0.5 mg/mL) of lysozyme-
(βCD)n/RNase A -(βCD)n and lysozyme/RNase A in 1×  PBS buffer, pH 7.4 at 25 °C was used 
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for all SPR experiments. SpotReady
TM
 16 chip (GWC Technologies, Madison, WI) were 
mounted in a dual channel flow cell and experiment was performed by first flowing 1× PBS, pH 
7.4 through the cell followed by a solution of lysozyme-(βCD)n/ RNase A-(βCD)n and 
unmodified lysozyme/RNase A in the same buffer and then finally flowing PBS. The amount of 
protein which adsorbs irreversibly on the gold was estimated by comparing the SPR intensity 
before and after the gold spots were exposed to the protein solution. 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
SDS-PAGE was conducted using BIO-RAD 7.5% Mini-PROTEAN
®
 TGX
™
 Precast Gel (BIO-
RAD, Hercules, CA). The protein sample (15 µL, 0.5 mg/mL or 0.05 mg/mL) was mixed with 5 
µL of deionized water and 5 µL of 5 × SDS-loading dye (Tris-Cl 0.25 M, pH 6.8, 10% SDS, 
50% glycerol, and 0.25% bromophenol blue). The mixture was heated to 90 ºC for 5 min and 20 
µL of each sample was loaded on to the gel. A protein ladder, Precision Plus Dual Color from 
BIO-RAD (BIO-RAD, Hercules, CA) was added in one of the wells for molecular weight 
reference. Tris-glycine (1×) was used as the running buffer for gel electrophoresis. The gel was 
run at 100 V for 80 min, and was washed with deionized water three times and stained with 
GelCode blue stain reagent (Thermo Scientific, Rockford, IL) for 1 h and then destained in 
deionized water overnight. The gel image was taken on the Alpha DigiDoc (Alpha Innotech, San 
Leandro, CA). 
Enzymatic Assay of lysozyme-(βCD)n and lysozyme 
Micrococcus lysodeikticus cells susupension (0.015% (w/v)) was prepared in 66 mM 
potassium phosphate buffer, pH 6.24. A solution containing 300 units/mL of lysozyme in cold 
potassium phosphate buffer was also prepared. A 2.5 mL of Micrococcus lysodeikticus cells 
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suspension was mixed with 0.10 mL of lysozyme by inversion and the decrease in absorbance at 
450 nm was recorded for approximately 5 min.  
Crystallization of Lysozyme and Lysozyme-(βCD)n  
Lysozyme and lysozyme-(βCD)n crystallized via vapor diffusion methods as hanging drops in 
48 well VDX plates (Hamilton Research, Aliso Viejo, CA) with sealent. All solutions were 
prepared using 50 mM sodium acetate buffer, (pH 4.59) at 25 °C. A stock solution of lysozyme 
(75.0 mg/mL) and lysozyme-(βCD)n (1.0 mg/13.5µL ~74.1 mg/mL) was prepared. Four 
reservoirs containing solutions of sodium chloride (958 mM) and 5’DSCG (5.47 mM) were 
separately prepared and sterile filtered through 0.22 µm syringe filters. 2.5 µL of lysozyme 
solution and lysozyme-(βCD)n were mixed with equal volume of reservoir solutions separately. 
The solution consisting of lysozyme and lysozyme-(βCD)n and reservoir solution was suspended 
on a siliconized coverslip as an inverted drop over a well containing 350 µL of the corresponding 
reservoir solution. Crystals were grown for a period of 2-4 d at rt and were viewed under the 
light microscope.  
General Information for Synthesis of βCD Amino Squarate Reagents 
 Reagents and solvents were reagent grade and used as supplied unless otherwise mentioned. 
Solvents were distilled under reduced pressure using Buchi rotary evaporator below 40 °C. EMD 
Silica Gel 60 F254 precoated plates (0.25-mm thickness) were used for TLC. Flash column 
chromatography was performed using SILICYCLE, Silica-P Flash Silica Gel with 40-63 μ mesh 
size. Proton and carbon-13 NMR spectra were recorded on 300 MHz, 
1
H chemical shifts were 
reported in ppm relative to CDCl3 δ 7.26 or D2O δ 4.80; 
13
C chemical shifts were reported 
relative to CDCl3 δ 77.23, and High Resolution Mass Spectra (HRMS) was recorded by positive 
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ion electrospray on a Bruker 12 Tesla APEX –Qe FTICR-MS with Apollo II ion source, unless 
otherwise reported.  
 
Synthesis of compound 2 
2
O O
O O
F
F
F
F  
Compound 1
85
 (1.40 g, 9.38 mmol) was dissolved in benzene (10 mL) and the solution was 
cooled to 0 ºC. 3,5-Difluorophenol (2.44 g, 18.7 mmol) was added to the above solution in one 
portion, followed by slow addition of excess of TEA (2.09 g, 20.6 mmol) and the reaction 
mixture was stirred at room temperature overnight. The reaction mixture was filtered and the 
residue obtained was washed with benzene to yield a white solid. The solid obtained was purified 
using flash silica gel column (20% EtOAc in hexanes) to give compound 2 (0.80 g, 27%) as a 
white solid. Rf = 0.59 (20% EtOAc in Hexanes). 
1
H NMR (300 MHz, CDCl3):  δ 6.90-6.88 (m, 
4H), 6.84-6.78 (m, 2H).
 13
C NMR (75 MHz, CDCl3): δ 186.2, 182.4, 165.3, 165.1, 161.9, 161.7, 
154.0, 153.6, 103.7, 103.5, 103.4, 103.3, 103.2, 102.9. HRMS found = 339.0280 [M + H]
 +
, calcd 
for [C16H6F4O4 + H] 
+ 
= 339.0275.  
Synthesis of compound 6 
OO
O N
H
6
F
F
 
Compound 5
89
 (10.0 mg, 0.008 mmol) was dissolved in water (0.5 mL). A solution of compound 
2 (6.00 mg, 0.017 mmol) in DMF (0.1 mL) was added to the above solution drop wise. Addition 
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of the solution of compound 2 to the reaction mixture was accompanied by precipitation of 2 as 
solid. Acetone was added drop wise to the reaction mixture to dissolve the precipitate and the 
reaction mixture was stirred at room temperature for 2 h. Excess acetone was added to the 
reaction mixture to precipitate out the crude product. The precipitated solid was washed 
thoroughly with acetone and dried under high vacuum to yield the pure compound 6 (7.60 mg, 
64%) as a pale yellow solid. 
1
H NMR (500 MHz, D2O): δ 7.19-7.15 (t, 1H, JH-H =10.0 Hz), 6.79-
6.64 (m, 2H), 5.13-5.01 (m 7H), 4.04-3.91 (m, 24H), 3.87-3.68 (m, 18H). Analyzed by MALDI-
TOF and matched [M + Na]
 + 
at 1364.64.  Expected Mass of sodium adduct: 1364.38. 
 
Synthesis of compound 3 
3
O O
O O
F F
 
Compound 3 was synthesized and purified by following procedures similar to those used for the 
synthesis of compound 2.  Rf = 0.51 (20% EtOAc in hexane). 
1
H NMR (300 MHz, CDCl3): δ 
7.26-7.23 (m, 4H), 7.17-7.09 (m, 4H), 
13
C NMR (75 MHz, CDCl3): δ 187.3, 182.9, 162.7, 159.4, 
149.2, 120.6, 120.5, 117.2, 116.9. Low resolution GC-MS found = 302 [M]
 +
, calcd for 
[C16H8F2O4] 
+ 
= 302.04. 
Synthesis of compound 7 
OO
O N
H
7
F
 
Compound 7 was synthesized and purified by following procedures similar to those used for the 
synthesis of compound 6. 
1
H NMR (500 MHz, D2O): δ 7.38-7.35 (m, 2H), 7.22-7.20 (m, 2H), 
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5.07-5.06 (m, 7H), 3.98-3.85 (m, 24H), 3.68-3.55 (m, 18H). Analyzed by MALDI and matched 
on [M + Na]
 +
at 1346.54.  Expected Mass of sodium adduct: 1346.39. 
Synthesis of compound 8 
OO
O N
H
8  
Compound 8 was synthesized and purified by following procedures similar to those used for the 
synthesis of 6. 
1
H NMR (500 MHz, D2O): δ 7.66-7.64 (m, 2H), 7.56-7.53 (m, 1H), 7.19-7.18 (m, 
2H), 5.07-5.05 (m, 7H), 3.98-3.83 (m, 24H), 3.69-3.62 (m, 18H). Analyzed by MALDI and 
matched on [M + Na]
 +
at 1329.24.  Expected Mass of sodium adduct: 1329.14. 
Synthesis of compound 10 
N
O
O
O
O
OCH3
O
10  
To a solution of compound 9 in anhydrous DCM (3 mL), added NHS (0.068 g, 0.593 mmol) and 
DCC (0.122 g, 0.591 mmol) at 0 °C. Stirred reaction mixture at 0 °C for 30 min and allowed the 
reaction mixture to come to rt. The reaction mixture was stirred at room temperature overnight. 
The reaction mixture was filtered to remove dicyclohexyl urea (DCU). The filtrate was 
concentrated under vacuum to remove solvent and the crude product was obtained as colorless 
oil. The crude product was purified using flash silica gel column (gradient 10%          40% 
EtOAc in Hexane) to obtain compound 10 as a white solid in quantitative yield. Rf = 0.44 (50% 
EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 3.62 (s, 1H), 2.80 (s, 4H), 2.56 (t, JH-H = 6, 
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2H), 2.27(t, JH-H = 6, 2H), 1.73-1.58 (m, 2H), 1.37-1.29 (m, 4H). 
13
C NMR (75 MHz, CDCl3): δ 
174.3, 169.3, 168.7, 51.6, 34.0, 31.0, 28.9, 28.8, 28.6, 25.7, 24.9, 24.6. HRMS found = 322.1261 
[M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 322.1258. 
Synthesis of compound 11 
N
H
O
OCH3
O
11
 
To a solution of compound 10 (0.053 g, 0.177 mmol) in DMF (2 mL) added compound 5 (0.240 
g, 0.211 mmol). The reaction mixture was stirred at rt for 48 h. The crude product was 
precipitated by acetone. The product was washed with acetone 2-3 times to obtain a compound 
11 as white solid (0.090g, 40%). Rf  = 0.46 (t-BuOH: EtOH: H2O, 3.3:2.6:1). 
1
H NMR (300 
MHz, DMSO): δ 7.56 (s, 1H), 5.77-5.64 (m, 14H), 4.80 (s, 1H), 4.45-4.42 (m, 6H), 3.64-3.60 (br 
m, 19H), 3.56 (s, 3H), 3.34-3.29 (br m, 12H), 2.25 (t, JH-H = 9, 2H),  2.23-2.063 (m, 2H), 1.47-
1.43 (m, 3H), 1.21 (s, 4H). HRMS found = 1340.4831 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
= 
1340.4849. 
Synthesis of compound 12 
N
H
O
OH
O
12
 
To a solution of compound 11 in DMSO (60 µL), added 1N NaOH (440 µL).  Stirred the 
reaction mixture at rt for 3 h. Neutralized the reaction mixture with 1N HCl. Product was 
precipitated out using acetone. The product was washed with acetone 2-3 times to obtain 
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compound 12 as white solid. Rf = 0.40 (t-BuOH: EtOH: H2O, 3.3:2.6:1). 
1
H NMR (300 MHz, 
DMSO): δ 7.72 (s, 1H), 5.78 (br m, 14H), 4.87-4.79 (m, 6H), 3.6 (br m, 37H), 2.50-2.47 (m, 4H), 
2.05-1.90(m, 3H), 1.40-1.18 (m, 4H). HRMS found = 1326.4738 [M + Na]
 +,
 calcd for 
[C12H18O6+Na] 
+ 
= 1326.4692. 
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Chapter 3 
Inducing Folding in an Inherently Unstructured Protein by Covalent Modification with 
Squarate Derivatives 
Summary 
Motivated by the fact that covalent modification with βCD can stabilize the folded structure of 
proteins, the ability of βCD to induce folding in entirely unfolded proteins was explored. 
Collaborating with Professor Jin Montclare at New York University-Polytechnic, I used cartilage 
oligomeric matrix protein (COMP) in which a single amino acid mutation of leucine 44 to 
alanine in the coiled coil domain of COMP (COMPcc) caused a complete loss of the α-helical 
structure. Chemical modification of the lysine residues of COMPcc mutant L44A with β-
cyclodextrins (βCD) via a squaramide linkage folded the protein into a α-helix. Interestingly, 
modification of L44A with methyl squarate alone also folded the protein into a α-helix. Small 
molecules such as curcumin exhibited an increase in the fluorescence signal upon binding to 
L44A-(βCD)n, which likely suggests that the folding stability of the protein is either enhanced or 
preserved. These results suggest that the chemical modification of L44A with βCD or methyl 
squarate changes the energy landscape of the protein and creates a new global minimum.  
3.1 Background and Significance 
3.1.1 Protein folding  
Protein folding is a process in which an unfolded protein having a distorted structure, folds 
into a well-defined tertiary structure with a specific function.
112
 Understanding the science of 
how proteins fold from a random coil to a three dimensional structure is highly desired due to the 
large implications of this process in the field of biology, biotechnology and human diseases.
113
 
Often folding involves the establishment of secondary structures, particularly alpha helices and 
beta sheets followed by establishment of tertiary structures.
114
 The de novo design of peptides 
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and proteins has recently emerged as an approach for investigating protein structure and 
function.
115
   
3.1.2 Inducing peptide and protein folding 
A variety of designed helical peptides and proteins provide great model systems to study the 
different interactions that stabilize the tertiary structure of proteins. A protein can fold 
spontaneously during or after biosynthesis or can be forced to fold using artificial chaperones or 
under varying salt concentrations and temperatures. Chaperones prevent misfolding or 
aggregation which may occur due to changes in the cellular environment.
116
  
“Peptide stapling” is a strategy in which an all-hydrocarbon cross-link is generated within natural 
peptides. It is a new approach for dramatically increasing the helicity and potency of peptides. 
This strategy of stapling peptides has largely been applied to B-cell lymphoma 2 (Bcl-2) family 
proteins which are dominant activators and inhibitors of apoptosis. It has been demonstrated that 
stapled helices are viable drug candidates for a wide variety of human cancers.
117-118
 Hodges and 
coworkers have reported the synthesis for three peptide analogs of the helix-loop-helix Ca
2+  
binding unit, which have a sequence similar to rabbit skeletal troponin C site (TnC). They 
observed that addition of Ca
2+
 induced conformational changes and induced secondary structure 
in TnC.
119
 Uversky, Fink and coworkers have studied the anion-induced folding of 
Staphylococcal Nuclease. 
120
   
The amyloid β-protein (Aβ) is a peptide, which is required for the activation of kinase 
enzymes, protection against oxidative stress, regulation of cholesterol transport,
 
transcription and 
anti-microbial activity. Besides these important functions in the body, the Aβ fibrils are also the 
principal protein component in Alzheimer’s disease (AD). It is believed that a small number of 
stacked, extended, ribbon-like β-sheets form the Aβ fibril.121 Teplow and co-workers have used 
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circular dichroism to show that a transient increase in helicity is observed immediately before the 
appearance of β-structure. Understanding the oligomerization of Aβ is important for developing 
strategies to block this process Aβ fibril formation and is of significant therapeutic value for 
treating AD.
122-123
 
Carbohydrates and their derivatives are known to stabilize protein folding. For example, 
artificial chaperones such as cyclodextrins are known to assist in protein folding and refolding. 
Gellman and coworkers have used cyclodextrins as artificial chaperones that can refold proteins, 
likely by stripping the detergents that are associated with the denatured proteins.
46-47, 53
 Here, the 
disruption of hydrophobic interaction between proteins or between protein and surfactant 
prevents aggregation and supports protein refolding. 
3.1.3 Cartilage oligomeric matrix protein (COMP) - function and uses 
Cartilage oligomeric matrix protein (COMP) is glycogenic protein present in the cartilage, 
tendons, ligaments and osteoblasts and has a pentameric bouquet like structure with a molecular 
mass of 524 kDa. The COMP is comprised of various domains and is assembled into a 
homopentamer via a N-terminal coiled-coil domain (COMPcc). The coiled-coil domain is a 
common structural motif found in proteins and consists of two to five α-helices wrapped around 
each other.
124
 The pentameric bundle of COMP is built of 230 amino acid residues. Five chains, 
each with 46 residues, form a parallel coiled-coil structure.
125
 The coiled-coil domains in 
proteins are capable of selectively storing and delivering small molecules. COMPcc has the 
ability to store and bind molecules such as vitamin D, all-trans retinol (ATR), retinoic acid, 
curcumin, benzene and cyclohexane (Figure 3.1).
126-127
 One major role of COMP is storage and 
delivery of regulatory molecules in bone metabolism. 
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Figure 3.1 (A) Structure and amino acid sequence of the monomer of COMPcc. (B) Chemical 
structures of small molecules that can bind to the hydrophobic cavity of COMPcc.  
3.1.4 Studying folding of an inherently unfolded protein by covalent modification with β-
cyclodextrins 
Montclare and coworkers have reported that the N-terminal aliphatic residues L37, L44, V47, 
and L51 of the coiled-coil region of COMP are necessary for maintaining its helical content, 
pentameric structure, stability and small molecule binding ability.
127
 The original COMPcc 
sequence has two cysteine residues near the C-terminus, which form disulfide bridges to stabilize 
the pentameric structure. In order to avoid complications due to oxidation, the N-terminal 
cysteines of COMPcc were mutated to serines to produce the mutant COMPcc
s
. The L44A is a 
mutant of COMPcc
s
, where leucine 44 is mutated to alanine (Figure 3.2). The replacement of 
leucine 44 with alanine results in a significant loss of the α-helicity of L44A.127 Montclare and 
coworkers suggest that the leucine residue probably interacts with residues at the i+3 positions to 
stabilize the α-helical structure. Hence, mutation of leucine 44 to alanine prevents α-helix 
formation. Recently, Luk and coworkers have reported that covalent grafting of proteins with β-
cyclodextrins (βCD) can prevent aggregation, surface adsorption and increase thermal stability of 
proteins.
128
 In this chapter of the dissertation, covalent modification of the COMPcc
s
 mutant 
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L44A with βCD using water driven ligations is presented. The ability of βCD to promote folding 
and induce α-helical structure into the completely unstructured protein L44A is demonstrated. 
 
 
Figure 3.2 (A) Amino acid sequence of COMPcc
s
 monomer, where the mutation site leucine 44 
is indicated in red. (B) Amino acid sequence of COMPcc
s
 monomer, where leucine 44 is 
converted to alanine 44. All lysine residues are represented in bold black font. 
3.1.5 Protein energy profile 
The native protein conformation is a stable three-dimensional structure that determines its 
biological function. Denatured proteins exist in a set of partially folded states. The folding 
process is described using a free-energy funnel where the unfolded states have high energy and 
entropy. As protein folding begins, the free energy drops and the number of conformational 
states decreases. The metastable protein can be trapped in the local minima’s along the way, 
which can slow down its progress towards the free energy minimum. As the protein folds, the 
narrowing of the energy funnel indicates the decrease in the number of conformations exhibited 
by the protein and the bottom of the well is referred to as the global minimum.
129-130
 I believe 
L44A does not have an existing global minimum, but covalent modification of L44A with βCD 
will create a new global minimum, lowering the entropy and energy of the protein (Figure 3.3). 
This mechanism of induced folding in unstructured proteins has potential to introduce new 
functions in the proteins and make not - so - useful proteins useful. 
109 
 
 
 
 
Figure 3.3 Proposed energy landscape for (A) L44A and (B) L44A-(βCD)n. 
3.2 Results and Discussion 
3.2.1 MALDI-TOF confirms modification of L44A with βCD 
The lysine residues in L44A were covalently modified with βCD using the βCD amino 
squarate compound 1 (Scheme 3.1). The hydrolytic stability and reactivity of amino squarates 
makes these molecules ideal for modifying proteins with βCD. 
Scheme 3.1 L44A modification with βCD 
 
 
 
 
 
 
I used matrix assisted laser desorption ionization time of flight (MALDI-TOF) spectroscopy to 
determine the degree of modification of L44A with βCD. I observed that up to three lysine 
residues in L44A were successfully conjugated to βCD using compound 1 (Figure 3.3A). 
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Nevertheless, some unreacted L44A was still observed by MALDI-TOF. After the reaction of 
L44A with compound 1, the unreacted reagents and other small molecules were removed by 
dialysis in phosphate buffered saline (PBS), pH 7.4. Dialyzing the sample subsequently in 
deionized water resulted in significant reduction in the mass peak of unmodified L44A (Figure 
3.4B). This suggests that unmodified L44A formed aggregates on dialysis in water, which were 
removed by filtration, whereas the βCD modification stabilized the protein structure and 
prevented the modified proteins from forming aggregates. It is interesting to note that prior to 
dialysis in water, when the L44A-(βCD)n  is in PBS buffer, the intensity of the mass peak in the 
MALDI-TOF spectrum corresponding to the first modification is higher than that of the second 
modification. However, after dialysis in water and subsequent filtration of the protein solution 
through a 0.2 µm syringe filter, the intensity of the mass peak in the MALDI-TOF spectrum 
corresponding to the second modification is considerably higher than that of the first 
modification. The above observation suggests that modification of L44A with at least two βCD 
groups is essential to prevent aggregation. Only the unmodified L44A and some of the L44-
(βCD)1 formed aggregates during the stress of dialysis in deionized water. 
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Figure 3.4 MALDI-TOF spectra for L44A-(βCD)n (A) after dialysis in deionized water without 
filtering through 0.2 µm pore filter (B) after dialysis in deionized water with filtering through 0.2 
µm pore filter. 
3.2.2 Circular dichroism indicates folding of L44A-(βCD)n 
Circular dichroism was conducted to determine if covalent modification of L44A with βCD 
can induce secondary structure in L44A. Alpha-helix, beta-sheet, and random coil structures 
each give rise to a characteristic shape and magnitude in the circular dichroism spectrum.
131
 
While L44wt shows the characteristic shape of α-helix, L44A has the characteristic shape of 
random coil. Circular dichroism was conducted on samples containing a mixture of unmodified 
L44A+L44A-(βCD)n and purified L44A-(βCD)n  alone (where n can range from 1 to 4). The 
results from circular dichroism on both the samples indicated presence of α-helical structure. The 
lower signal intensity in purified L44A-(βCD)n may be due to difference in the concentration of 
the two proteins (Figure 3.5). I believe that folding is induced in L44A-(βCD)n  because the 
multiple hydroxyl groups on βCD act as a template to generate a structured solvation shell as a 
result of low dynamic hydrogen bonding between the hydroxyl groups on βCD and the water 
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molecules. Another possibility for induced folding in L44A-(βCD)n  could be non-covalent 
stapling resulting from intra-molecular interaction between  hydrophobic amino acid residues 
and βCD.   
 
Figure 3.5 Circular dichroism spectra for L44wt, L44A, L44A-(βCD)n, and L44A-(βCD)n 
purified. Circular dichroism was conducted by Jasmin Hume in Professor Jin Montclare’s 
laboratory at Polytechnic Institute of New York University. 
To determine the significance of covalent modification of L44A with βCD to induce folding or 
any structural change, control experiments were conducted where free βCD was added to L44A 
(29 µM) and L44wt protein (29 µM) (Figure 3.6 and 3.7). L44A and L44wt were treated with 
increasing concentrations of free βCD and circular dichroism was conducted on the protein 
samples. In general, addition of βCD to L44wt and L44A resulted in a decrease and increase in 
the circular dichroism signal with increasing concentrations of added βCD respectively, but did 
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not bring any change to the protein structure. However covalent conjugation of βCD to L44A 
induced α-helical structure in the protein. 
 
Figure 3.6 Circular dichroism spectra for L44A treated with free βCD. Circular dichroism was 
conducted by Jasmin Hume in Professor Jin Montclare’s laboratory at Polytechnic Institute of 
New York University. 
 
Figure 3.7 Circular dichroism spectra for L44wt treated with free βCD. (Circular dichroism was 
conducted by Jasmin Hume in Professor Jin Montclare’s laboratory at Polytechnic Institute of 
New York University). 
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3.2.3 Dynamic light scattering to measure the size of L44wt, L44A and L44-(βCD)n  
 
Dynamic light scattering (DLS) was used to measure the hydrodynamic diameter of L44 wt, 
L44A and L44A-(βCD)n. The concentration of all protein solutions used for the study was ~29 
µM. The hydrodynamic diameter of unmodified L44A and L44wt was found to be18.4 nm 20.4 
nm respectively (Figure 3.8). Native lysozyme (14 kDa) which has a molecular weight that is 
twice that of the molecular weight of L44A (6.9 kDa), has a hydrodynamic diameter of only 4.4 
nm. This suggests that L44A has a hydrodynamic diameter which is ~ 4 times larger than that of 
lysozyme. The hydrodynamic diameter of lysozyme-(βCD)n (n can range from 1 to 6) and RNase 
A-(βCD)n (n can range from 1 to 10) has been reported to be similar to unmodified lysozyme and 
RNase A respectively.
128
 I believe the relatively large hydrodynamic diameter exhibited by 
L44A may be due to the lack of a defined structure. It is surprising that modification of L44A 
with βCD causes such a significant (almost double) increase in the hydrodynamic diameter for 
L44A-(βCD)n . I believe the large hydrodynamic diameter exhibited by L44A-(βCD)n is likely 
due to formation  of a pentameric assembly formed by the folded protein. One likely mechanism 
for assembly formation by L44A-(βCD)n  is non-covalent inter-molecular interaction of the 
pendant βCD groups with amino acid residues on the adjacent protein. 
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Figure 3.8 Number distribution of DLS showing two replicates each of (A) L44A (B) L44wt (C) 
L44A-(βCD)n and (D) lysozyme in PBS buffer pH 7.4 at 25 °C. 
3.2.4 Influence of groups like acetyl, polyethylene glycol (PEG) and methyl squarate on folding 
of L44A 
Modification of the lysine residues in L44A with βCD results in removal of charge due to 
modification of the lysine residues, addition of a squaramide and βCD moiety. In order to 
determine which of the above factors are responsible for inducing folding in L44A, I modified 
L44A with compounds 2, 3 and 4 (Scheme 3.2).  
Scheme 3.2 Molecules synthesized to study the influence of groups like acetyl, polyethylene 
glycol (PEG) and methyl squarate on folding of L44A 
 
 
 
32
O O
O CH3
ON
O
O
CH3
O
H
N
O
N
O
O nO
O
4
O
CH3
116 
 
 
 
Compound 2 was synthesized and used to covalently modify the lysine residues with an acetyl 
group, thereby removing the positive charge on the lysine residues (Figure 3.8A). Compound 3 
was synthesized to covalently modify the lysine residues in L44A, to study the effect of methyl 
squarate moiety alone on the folding of L44A (Figure 3.8B). Since its development in the 1970s, 
modification of proteins with poly(ethylene) glycol (PEG) has remained a major approach to 
reduce protein aggregation.
132-133
 Surfaces functionalized with PEG are known to resist protein 
adsorption.
134-135
 The resistance of PEG towards protein adsorption on surfaces is believed to be 
due to the steric repulsion effect, where the PEG chains prevent the protein from reaching the 
surface for adsorption.
136
 Modification of proteins with PEG is known to increase the stability of 
proteins and also prevent protein aggregation.
18
 Hence, the lysine residues in L44A were 
covalently modified with PEG using compound 4 (Figure 3.9C), to study the influence of the 
pendant PEG groups on folding and stability against aggregation of L44A. 
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Figure 3.9 Lysines of L44A modified with (A) compound 2, (B) compound 3 and (C) compound 
4. 
Matrix assisted laser desorption ionization time of flight (MALDI-TOF) indicated that up to 
five acetyl groups were grafted covalently on to L44A. Since L44A has only three lysine 
residues, it seems that amino acids other than lysine also reacted with compound 2 and hence up 
to five modifications were observed (Figure 3.10). Mass spectra also confirmed that up to three 
lysine residues in L44A were modified with compounds 3 (Figure 3.11) and compound 4 (Figure 
3.12). However, unmodified L44A was observed along with the modified proteins in all the three 
modification experiments. 
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Figure 3.10 MALDI-TOF spectra for L44A-(acetyl)n indicated that up to five acetyl groups were 
conjugated to L44A. 
 
 
Figure 3.11 MALDI-TOF spectra for (A) L44A-(methyl squarate)n  indicated that up to three 
methyl squrates were conjugated to the lysine residues of L44A. 
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Figure 3.12 MALDI-TOF spectra for L44A-(PEG)n  indicated up to three PEG chains were 
conjugated to the lysine residue of L44A.  
To measure the ability of compounds 2, 3 and 4 to induce folding in L44A, circular dichroism 
was conducted on the samples containing a mixture of unmodified L44A+ L44A-(acetyl)n, 
unmodified L44A + L44A-(methyl squarate)n, and  unmodified L44A + L44A-(PEG)n (Figure 
3.13). Interestingly, L44A modified with methyl squarate exhibited α-helix formation. However, 
L44A modified with acetyl and PEG groups did not exhibit any folding. Hence, this suggests that 
modifying the unfolded protein sequence L44A with βCD or methyl squarate alone causes the 
protein to fold into an α-helix, while modifying the same unfolded sequence with  PEG does not 
induce any folding. 
The folding exhibited by L44A-(methyl squarate)n  eliminates the possibility that the induced 
folding in L44A-(βCD)n might be because of the interaction of βCD with the hydrophobic amino 
acids in L44A. I believe, due to the rigid structure and presence of the two carbonyl groups in the 
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methyl squarate, it can strongly hydrogen bond with surrounding water molecules and hence 
induce folding as hypothesized previously for L44A-(βCD)n.  
 
Figure 3.13 Circular dichroism spectra for L44A modified with compounds 1, 2, 3 and 4. 
Concentration of L44A-(methyl sq)n = 29.65 µM, L44A-(acetyl)n = 8.27 µM  L44A-(PEG)n = 
23.45 µM. Circular dichroism was conducted by Jasmin Hume in Professor Jin Montclare’s 
laboratory at Polytechnic Institute of New York University. 
Dynamic light scattering was used to determine the size of L44A-(acetyl)n,  L44A-(methyl 
squarate)n, and  L44A-(PEG)n. Keeping L44wt as standard for explaining extent of assembly 
formation, I believe that L44wt is folded and exists as a pentameric assembly and exhibits a 
hydrodynamic diameter of 18.4 nm. L44A exhibits a hydrodynamic diameter of 21.7 nm 
suggesting mild denaturation and aggregation. L44A-(βCD)n which showed folding into an α-
helix exhibited a hydrodynamic diameter of 42.9 nm, which was almost twice the diameter of 
L44wt, indicating folding and formation of a high order assembly. Surprisingly, L44A-(methyl 
squarate)n  which was able to induce folding in L44A, exhibited a hydrodynamic diameter of 152 
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nm, which was much higher than the hydrodynamic diameter of L44A-(βCD)n. This observation 
suggests that covalent modification of L44A with methyl squarate results in the formation of a 
multi order assembly. L44A-(PEG)n  showed a hydrodynamic diameter of 3.7 nm, which is 
closer to the average diameter of COMPcc monomer.
125
 The small hydrodynamic diameter 
exhibited by L44A-(PEG)n could be due to the steric repulsions between the PEG chains, which 
are able to keep L44A-(PEG)n in monomeric form. L44A-(acetyl)n  showed very high 
hydrodynamic diameter suggesting complete denaturation and aggregation (Table 3.1).  
Table 3.1 Secondary structure and hydrodynamic diameter of modified L44A with different 
chemical agents. 
 
3.2.5 Small molecule binding by L44A-(βCD)n 
The coiled coil domain of COMPcc is capable of binding small molecules such as vitamin D, 
trans-retinol (ATR), retinoic acid and curcumin.
126-127
 Since the covalent modification of L44A 
with βCD can induce folding in L44A, the ability of L44A-(βCD)n to bind such small molecules 
was also studied. The binding of curcumin by L44A-(βCD)n was monitored using fluorescence 
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spectroscopy. We discovered that binding of curcumin with L44A-(βCD)n was associated with 
enhancement of fluorescence suggesting strong  binding of curcumin with L44A-(βCD)n. 
Past Studies show that curcumin and βCD exhibit weak host guest binding     
Tang and coworkers have studied the supramolecular interaction of curcumin and βCD by 
spectrophotometry.
137
 They discovered that βCD binds with curcumin to form a 2:1 host-guest 
complex with a formation constant of 5.53 × 10
5
 mol
-2
L
2
. The formation constant was 
determined at pH 2.4 in water/acetonitrile medium. Maximum absorbance was observed at 431 
nm when the concentration of curcumin and βCD was 1×10-5 mol/L and 5.0 × 10-3 mol/L 
respectively. 
Wagner and coworkers have studied fluorescence enhancement for curcumin upon inclusion 
into cyclodextrins or modified cyclodextrins.
138
 The fluorescence enhancement was studied for 
all CDs (10 mM) with 1 × 10
-5 
M of curcumin in 1% methanol/water system. They found that for 
both parent and modified CDs, βCD gave a larger enhancement in the fluorescence signal than 
αCD. However, γCD showed a higher fluorescence enhancement compared to βCD. The authors 
discovered that curcumin forms 2:1 host-guest inclusion complexes with these CDs and the 
strongest binding was exhibited by αCD (K1= 3300 M
-1
, K2=5.4 M
-1 
and K1K2= 18000 M
-2
) and 
hydroxypropylated (HP) βCD (K1= 3400M
-1
, K2=120 M
-1 
and K1K2= 41000 M
-2
). However, 
βCD alone exhibited weaker binding constants (K1= 280 M
-1
, K2=6.6 M
-1 
and K1K2= 1800 M
-2
).  
Swaroop and coworkers have characterized the 1:1 inclusion complex of curcumin and βCD 
using absorption and fluorescence spectroscopy.
139
 They discovered that the fluorescence 
intensity increased with increase in concentration of βCD. At 10 mM βCD and 10 µM of 
curcumin, a well-defined blue shifted band was observed at λmax =520 nm. The binding constant 
for the 1:1 complex was found to be 5.2 ×10
3
 M
-1
. 
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Binding study using L44A-(βCD)n suggests enhanced binding of curcumin in the hydrophobic 
pocket of the pentameric assembly and not in the βCD 
We studied the binding of curcumin (145 µM) with L44A-(βCD)n  (29 µM) and discovered 
that curcumin exhibited an enhancement in fluorescence upon binding with L44A-(βCD)n 
(Figure 3.14). This suggests that curcumin binds within the hydrophobic pore of the pentameric 
assembly formed by L44A-(βCD)n. We observed no enhancement in the fluorescence signal 
when 58 µM of βCD was incubated with 145 µM of curcumin. This suggests that there is no 
potential binding between βCD and curcumin at the tested concentrations. We note that buffer 
(phosphate buffer) and L44A alone do not influence the fluorescence signal of curcumin. One 
major question about modifying proteins with βCD is whether their folding stability or activities 
is preserved, enhanced or reduced. The increase in fluorescence signal observed during the 
binding study of L44A-(βCD)n with curcumin likely suggests that the folding stability of the 
protein is either enhanced or preserved. In chapter 2 of this dissertation, I have demonstrated that 
modifying lysozyme with βCD prevents aggregation, surface adsorption and increases thermal 
stability but reduces the activity of lysozyme-(βCD)n. Here, we discover that modifying L44A 
with βCD not only folds the random coil sequence but also promotes pentameric assembly 
formation accompanied by enhanced binding to small molecules such as curcumin by L44A-
(βCD)n. The enhancement in fluorescence could also be due to the higher effective concentration 
of L44A-(βCD)n, which likely results in binding of more curcumin molecules. Given that the 
concentration of the L44A-(βCD)n and L44A is same, the enhancement in absorbance is 
probably due to enhanced folding stability of L44A-(βCD)n. 
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Figure 3.14 Fluorescence spectra for curcumin binding in the hydrophobic pocket of L44A-
(βCD)n. PB in the fluorescence spectra stands for phosphate buffer (pH 8.0). (Fluorescence study 
has been conducted by Jasmin Hume in Professor Jin Montclare’s laboratory at Polytechnic 
Institute of New York University). 
3.2.6 Breaking the assembly formation in L44A-(βCD)n 
The mixture of unmodified L44A+L44A-(PEG)n exhibited a hydrodynamic diameter of 3.7 
nm, which is believed to be the expected hydrodynamic diameter of L44A and L44wt.
125
 In order 
to break the assembly formation of L44A-(βCD)n,  an adamantane tetra(ethylene glycol) (TEG) 
conjugate (adamantane-TEG) was synthesized using literature reported procedures.
140
 The 
adamantane-TEG can potentially form a non-covalent inclusion complex with the βCD attached 
covalently to the lysine residues of L44A and render the protein monomeric due to steric 
repulsions between the TEG chains (Figure 3.15).  
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Figure 3.15 Strategy for preventing assembly formation of L44A-(βCD)n. (A) Assembly 
formation in L44A-(βCD)n  due to hydrogen bonding between βCD molecules (B) Repulsions 
between TEG chains conjugated to adamantane, which forms inclusion complex with covalently 
grafted βCD molecules, keeps the proteins monomeric. 
Several methods were tried to form an inclusion complex between βCD covalently conjugated 
with L44A and adamantane-TEG. One of the methods involved the treatment of the mixture of 
L44A+ L44A-(βCD)n  (29 µM) with excess amount of adamantane-TEG (100 eq) for 24 h. 
Dynamic light scattering indicated that the size of the mixture of L44A+ L44A-(βCD)n  was ~ 88 
nm. Addition of adamantane-TEG reduced the size of L44A+ L44A-(βCD)n  to ~ 38 nm. This 
result suggests that the large assembly size of the L44A+ L44A-(βCD)n  was broken due to 
formation of inclusion complex between the βCD and the adamantane-TEG, resulting in the 
decrease in the hydrodynamic diameter by almost half.  
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3.2.7 Purification of L44A-(βCD)n using reverse phase HPLC 
In order to study how many βCD moieties are required for inducing folding in L44A, it is 
important to separate out proteins with different degree of modifications and study their folding 
individually using circular dichroism. The MALDI-TOF results suggested that at least two βCD 
moieties are essential for preventing aggregation of L44A-(βCD)n . I further believe that at least 
two βCD moieties may also be essential for stabilizing the folded structure of L44A-(βCD)n.  
The separation of different degree of modification in L44A-(βCD)n was attempted using reverse 
phase high performance liquid chromatography (HPLC) using a C18 column. The L44A-(βCD)1 
and L44A-(βCD)2 were successfully separated out  and the different elution times for L44A-
(βCD)1  and L44A-(βCD)2 from the C18 HPLC column are shown in table 3.2. 
Table 3.2 Elution times for L44A-(βCD)1  and L44A-(βCD)2  from a C18 HPLC column 
(eluents: water -0.1%TFA/acetonitrile-water-0.1% TFA). 
 
 
After elution from HPLC, MALDI-TOF was conducted on the eluted fractions to confirm the 
extent of purification of L44A-(βCD)n.  MALDI-TOF indicated that the L44A-(βCD)1  was 
almost 100% pure whereas the  L44A-(βCD)2 had small amounts of L44A-(βCD)1. 
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Figure 3.16 MALDI-TOF spectra for purified (A) L44A-(βCD)1 and (B) L44A-(βCD)2  using 
reverse phase HPLC. 
 
3.2.8 Effect on thermal stability of lysozyme by modification with compounds 2 and 3  
Luk and coworkers have reported that covalent modification of lysozyme with βCD increases 
the thermal stability of the protein against aggregation.
128
 Since covalent modification of L44A 
with methyl squarate alone induced α-helix structure in L44A, I further explored how the thermal 
stability of lysozyme against aggregation would be affected, if the lysine residues in lysozyme 
were covalently modified with acetyl and methyl squarate groups.  
Gorgani and coworkers have reported that acetylation of the lysine residues in lysozyme 
promotes amyloid formation resulting in formation of more pronounced fibrils.
141
 Hence the 
proposed study can help us determine whether the positive charge on the lysine residues in 
lysozyme is essential for maintaining the thermal stability against aggregation of lysozyme. 
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The positive charges on lysozyme were blocked by acetylating the lysine residues using 
compound 2 and squarylating the lysine residues using compound 3 at pH 8.2 for 72 h. MALDI-
TOF showed that up to four acetyl (Figure 3.17A) and four methyl squarate groups (Figure 
3.17B) were conjugated to the lysine residue of lysozyme.  
 
 
Figure 3.17 MALDI-TOF spectra for lysozyme modified with (A) compound 2 and (B) 
compound 3. In both the modifications, some amount of unmodified lysozyme was also 
observed.  
The thermal stability against aggregation for lysozyme-(acetyl)n and lysozyme-(methyl 
squarate)n  was compared to lysozyme-(βCD)n. All the lysozyme modifications reactions with the 
three chemical agents contained some amounts of unmodified lysozyme. The thermo-induced 
aggregation study was conducted using dynamic light scattering. During the thermo-induced 
aggregation of lysozyme-(acetyl)n and lysozyme-(methyl squarate)n, I observed that lysozyme-
(acetyl)n formed aggregates after 5 min of heating at 67 °C, whereas lysozyme-(methyl squarate)n   
formed aggregates after 5 min of heating at 57 °C. However lysozyme-(βCD)n formed 
aggregates at 77 °C after 5 min. Native lysozyme forms aggregates at 67 °C after heating for 25 
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min. Interestingly, the aggregate size formed by lysozyme-(βCD)n was smallest compared to 
lysozyme-(acetyl)n and lysozyme-(methyl squarate)n (Table 3.3) . These results indicate that the 
blocking the positive charges on the lysines residues in lysozyme results in a decrease in the 
thermal stability against aggregation of lysozyme. In case of lysozyme-(βCD)n the positive 
charges on the lysines are also getting blocked, but the grafted βCD on lysozyme is responsible 
for increase in the thermal  stability against aggregation. Studying the folding of   lysozyme-
(acetyl)n and lysozyme-(methyl squarate)n using circular dichroism can further help to determine 
if the structure of lysozyme was still preserved after blocking the positive charges on lysozyme. 
Table 3.3 Thermal stability of chemically modified lysozyme using dynamic light scattering 
(DLS) 
 
3.2.9 Generality of our system 
 The coiled coil domain is the most frequently occurring motif found in proteins.  A 
characteristic feature of the coiled coil domains is the occurrence of an amino acid heptad repeat  
(abcdefg)n , with predominantly hydrophobic residues at positions “a”  and “d” and polar 
residues elsewhere. Generally amino acids such as Leu, Ile, Val, and Ala are found at the “a” and 
“d” positions. Positions “e” and “g” frequently have charged residues that might contribute to 
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stability and the specificity of helix association.
142
 Despite an apparent simplicity at the sequence 
level, a large number of structural variations are observed among coiled coils.  
Thrombospondins 3 and 4 (TSP3 and TSP4) have the same bouquet like structure formed by the 
COMP. Furthermore, the sequence alignment of the coiled coil domains of COMP, TSP3 and 
TSP4 are very similar.
125
 This suggests that a single mutation in TSP3 and TSP4 may result in 
the loss of α-helicity of the protein and covalent modification with βCD and methyl squarate 
alone can help induce α-helicity in the mutated protein.  
Liu and coworkers have reported the engineering of a 52 residue protein (Ala14) that contains 
only alanine in the “a” and “d” positions of the natural heptad repeat sequence. Ala14 is unfolded 
under normal conditions and yet forms parallel three standed α-helical coiled coil crystals.143 
Because hydphobicity is a key feature for determining the stability of proteins, replacing a bulky 
hydrophobic group such as leucine with alanine is believed to result in a decrease in protein 
stabilization.
143-144
 Hodges and cowokers have designed de novo a two stranded α-helical coiled 
coil and found that  replacement of one large hydrophobic leucine with alanine decreases the 
stability of the coiled coils.
145
 Keating and coworkers report that the coiled-coil energy landscape 
is degenerate, where small changes in sequence can lead to large changes in structure.
146
 Clearly 
coiled coils are important structural motifs involved in a variety of important interactions that 
have the potential to be biochemically and therapeutically exploited. 
The protein p53 also known as TP53 or tumor protein is a gene that codes for a protein that 
regulates the cell cycle and hence functions as a tumor suppressor. The N-terminal region 
consists of an intrinsically disordered transactivation domain (TAD) and a proline-rich region.
147-
148
 One of the principle p53 regulator is Mdm2 or Hdm2, which binds directly to the TAD 
domain of p53 transactivation domain and targets p53 for proteasomal degradation. Upon 
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binding of the TAD domain of p53 to partner proteins, regions of nascent helical structure that 
are present in the native state rigidify and become fully folded.
149
  Reactivation of the p53 cell 
apoptosis pathway through inhibition of the p53-Hdm2 interaction is a viable approach to 
suppress tumor growth in many human cancers. Researchers have prepared synthetic p53 
analogs via a hydrocarbon cross-link (staple) to increase the stabilization of the helical 
structure.
117, 150
 Since the formation of a stabilized α-helix of TAD is important for Mdm2or 
Hdm2 binding, I believe covalent modification of the TAD domain with βCD can stabilize and 
induce folding in the TAD domain and help us in exploring therapeutically relevant peptides.  
3.3 Conclusions and Perspectives 
The cartilage oligomeric matrix protein (COMP) is a glycogenic protein present in the 
cartilage, tendons, and ligaments of osteoblasts and has a pentameric bouquet like structure. A 
single amino acid mutation of leucine 44 to alanine in the coiled coil domain of COMP 
(COMPcc) caused a complete loss of the α-helical structure for the mutant L44A. Covalent 
modification of L44A with βCD induced α-helical structure in the inherently unstructured L44A. 
Interestingly, covalent modification of L44A with methyl squarate alone also induced an α-
helical structure in unstructured L44A. One plausible mechanism for induced folding is that the 
multiple hydroxyl groups on βCD probably act as a template to generate a structured solvation 
shell, due to of low dynamic hydrogen bonding between the hydroxyl groups on βCD and water 
molecules. Dynamic light scattering showed that the hydrodynamic diameter of L44A-(βCD)n  
was around 42 nm, which was higher than the hydrodynamic diameter of proteins with higher 
molecular weights. Modifying L44A with βCD not only folded the random coil sequence but 
also promoted pentameric assembly formation and enhanced binding to small molecules such as 
curcumin within the hydrophobic core of this pentameric assembly. 
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Another branch of the same work can be inducing folding in unstructured peptides. Anderson 
and coworkers have designed a 20-residue self-folding peptide using only the standard set of L-
amino acids.
151
 Using such small folded proteins, one can design peptides, by decreasing the 
amino acid residues one at a time until the protein does not fold anymore. Once a peptide with 
acertain number of amino acids is acquired, refolding of the designed peptide can be studied by 
covalent modification with βCD. This approach can help in designing proteins with even less 
than 20 amino acid residues. 
The protein p53 is a tumor suppressor protein encoded by the gene TP53. Mdm2 is an 
important negative regulator of the p53 tumor suppressor, which binds to the transactivation 
domain (TAD) of p53. The TAD domain of p53 is intrinsically disordered and adopts a α-helical   
conformation upon binding to Mdm2. I have designed synthetic p53 mimics, which I will 
covalently modify with βCD to study if folding is induced in the βCD conjugated p53 mimics. If 
folding is induced in the designed p53 mimics, binding studies with the Mdm2 receptor can be 
done to explore the therapeutic potential of these peptides.  
3.4 Experimantal Section 
Materials and Methods 
L44A and L44wt were obtained from Professor Jin Montclare at from Polytechnic Institute of 
New York University. All other chemicals were obtained from Aldrich Chemicals (Milwaukee, 
WI). Phosphate buffered saline, 1× PBS (2.7 mM potassium chloride, 137 mM sodium chloride, 
8 mM sodium phosphate dibasic, 1.48 mM potassium phosphate monobasic) was used for all 
protein reactions unless mentioned (pH of the prepared buffers was adjusted using 1N HCl and 
1N NaOH). 
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Circular Dichroism 
Circular dichroism (CD) spectroscopy was conducted on a Jasco J-815 CD spectrometer. All 
proteins were at a concentration of 29 µM, unless otherwise mentioned. The wavelength 
spectrum was measured over a range from 190 to 250 nm with a step size of 1 nm.  
General Procedure for Modification of L44A with Different Chemical Agents 
Different chemical agents (~100 eq) were added to a solution of L44A (29 µM) in 1× PBS pH 
8.2 (reaction buffer).  The reaction mixture was stirred in a 28 ºC incubator shaker for 72 h. The 
reaction mixture was dialyzed in 250 mL 1× PBS, pH 7.4. MALDI-TOF was conducted on the 
protein samples to see the number of modification on the protein.  
Modification of lysozyme with Acetyl and Methyl Squarate Groups 
Compounds 2 (1.1 mg, 200 eq), 3 (1.70 mg, 200 eq) and 4 (2.16 mg, 100 eq) were added to a 
solution of lysozyme (1 mg/mL) prepared in 1× PBS pH 8.2 (reaction buffer) separately.  The 
reaction mixtures were stirred in a 28 ºC incubator shaker for 72 h. The reaction mixtures were 
dialyzed in 250 mL 1× PBS, pH 7.4 in separate dialysis cassettes. MALDI-TOF was conducted 
on the samples to see the number of modification on the protein.  
Dialysis 
The protein samples were dialyzed in 1× PBS and/or in water (dialysis media), using Slide-A-
Lyzer Dialysis Cassettes 3K molecular weight cut off (MWCO) purchased from Thermo 
Scientific (Rockford, IL). Before use, the Slide-A-Lyzer Dialysis Cassette was hydrated in the 
dialysis media for 5 min. Sample was injected in the cassette and placed in 250 mL of dialysis 
media to get rid of unreacted compound 6. The 1 × PBS was changed twice every 2 h for the first 
6 h and then left overnight. The same reaction mixture was further dialyzed in a new dialysis bag 
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in 250 mL of deionized water to promote aggregation of unreacted protein. The deionized water 
was changed twice every 2 h for first 6 h and then left overnight. Reaction mixture was then 
passed through a syringe filter (0.22 µm) to eliminate aggregated protein.  
Fluorescence Measurement for Curcumin Binding with L44A-(βCD)n  
Fluorescence measurements of L44A-(βCD)n  and curcumin binding was conducted with 29 
µM of L44A-(βCD)n  and 145 µM of curcumin in 10 mM  phosphate buffer, pH 8.0. Samples 
were incubated at rt for 1 h and fluorescence was measured using a SpectraMax Plus M2 
instrument with an excitation wavelength of 420 nm and an emission wavelength from 450-600 
nm. An emission maxima was observed for L44A-(βCD)n  and L44wt near 525 nm for curcumin 
binding. The fluorescence spectra was obtained after 2 h of incubation of curcumin with L44A-
(βCD)n , L44wt , L44A and βCD. 
Purification of L44A-(βCD)n Using High Performance Liquid Chromatography (HPLC) 
The separation of different degree of modification in L44A-(βCD)n were attempted using 
reverse phase high performance liquid chromatography (HPLC) from Shimadzu (Boston, 
Marlborough, MA) using a Alltima C18 5µm column (150 mm × 4.6 mm). The column was 
eluted at 1.75 ml/min with a gradient of water /0.1%TFA as eluent A and acetonitrile/water/0.1% 
TFA (90:9.9:0.1) as eluent B. The method used for purifying different degrees of modification is 
given in the table below. Eluted proteins were evaluated at 220 and 280 nm. 
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Method used for purifying different degrees of modification in L44A-(βCD)n 
 
Synthesis and Spectra Data 
Synthesis of compound 2 
O
O O
N
O
O
HO
THF, rt O
O
N
O
O
O
OH
2
  acetic 
anhydride
N-hydroxy
succinimide  
To a solution of acetic anhydride (0.088 g, 0.869 mmol) in THF (3 mL) N-hydroxy succinimide 
(0.100 g, 0.868 mmol) was added. Stirred the reaction mixture at rt for 1 h. Evaporated the THF 
to obtain pure compound 2 (0.127 g, 93%) as white solid. Rf = 0.59 (70% EtOAc in Hexane). 
1
H 
NMR (300 MHz, CDCl3): δ 2.78 (s, 4H), 2.30-2.28 (m, 3H). HRMS found = 157.0375 [M]
+
, 
calcd for [C6H7O4N] 
+ 
=157.0374.  
 
 
 
136 
 
 
 
 
Synthesis of compound 3a 
O OH
O O
O O
O O
1. MeLi, THF, -78°C to 0°C
2. aqueous workup
3,4-diphenoxy-3-cyclobutene-1,2-dione 3a  
1.6 M methyl lithium (0.70 mL, 1.125 mmol) in Et2O was added dropwise to a solution of 
diphenoxy-3-cyclobutene-1,2-dione (0.200 g, 0.751 mmol) in THF (10 mL) at -78 °C. The 
reaction was stirred -78 °C and was monitored by TLC until no more starting material was 
observed. Water was added dropwise at -78 °C to quench the reaction and reaction was slowly 
warmed up to rt. The aqueous phase was extracted with EtOAc. The combined organic layers 
were dried over anhydrous Na2SO4 and evaporation of organic solvents afforded the crude 
product as yellow oil. The crude product was purified using silica gel column (20% EtOAc in 
Hexanes) to afford pure compound 3a as colourless oil (0.110 g, 52%). Rf = 0.50 (40% EtOAc in 
Hexane). 
1
H NMR (300 MHz, CDCl3): δ7.41-7.18 (m, 7H), 7.11-7.06 (m, 1H), 6.96-6.92 (m, 
2H), 4.11 (s, 1H), 1.48 (s, 3H). 
Synthesis of compound 3 
O OH
O O
3a
HCl, DCM, rt
O O
O
3  
To a solution of compound 3a (0.066 g, 0.233 mmol) in DCM (2 ml) was added 3-5 drops of 12 
N HCl at rt. Stirred the reaction mixture at rt for 2 h. The reaction mixture was diluted with 
DCM and organic phase was washed with water (3 × 10 mL). The organic layer was dried over 
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anhydrous Na2SO4 and evaporation of organic solvents afforded the crude product as yellow oil. 
The crude product was purified using silica gel column (20% EtOAc in Hexanes) to obtain light 
yellow solid (0.044g, quantitative yield). The solid was recrystallised with ether, hexane and a 
few drops of acetone to obtain, white crystals of compound 3. Rf = 0.64 (40% EtOAc in Hexane). 
1
H NMR (300 MHz, CDCl3): δ 7.46-7.43 (m, 2H), 7.41-7.29 (m, 1H), 7.22-7.18 (m, 2H), 2.08 (s, 
3H). 
13
C NMR (75 MHz, CDCl3): δ197.3, 196.3, 191.5, 181.8, 153.5, 130.5, 127.5, 119.5, 10.4. 
HRMS found = 188.0468 [M + H]
 +
, calcd for [C11H7O3] 
+ 
= 187.0396.  
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Chapter 4 
Synthesis of an Adamantane-Platinum Conjugate Hosted in β-Cyclodextrin for Enhanced 
Activity and Targeted Drug Delivery
‡
  
 
Summary 
In this section of the dissertation, the synthesis of an adamantane-platinum conjugate (analog 
of carboplatin) hosted in β-cyclodextrin is reported. The cytotoxic activity of the carboplatin 
analog hosted in β-cyclodextrin was tested towards human neuroblastoma cells (SK-N-SH). This 
inclusion complex of βCD adamantane carboplatin analog exhibited higher cytotoxicity towards 
SK-N-SH cells than carboplatin. Agarose gel electrophoresis confirmed that this inclusion 
complex of βCD adamantane carboplatin analog exhibited higher binding to plasmid pBR322 
deoxyribonucleic acid (DNA) than carboplatin. Confocal fluorescence images showed that SK-
N-SH cells treated with FITC-tagged βCD exhibited green fluorescence in the vicinity of the  
nuclei of the cells, suggesting that FITC-tagged βCD were efficiently internalized into the cancer 
cells. The uptake rate at which carboplatin and the βCD adamantane carboplatin analog were 
taken up by the cancer cells was measured by inductively coupled plasma mass spectrometry 
(ICP-MS), which indicated that the uptake rate of carboplatin was about 4 times higher than 
βCD- adamantane carboplatin analog. The higher cytoxicity of the inclusion complex than 
carboplatin towards SK-N-SH cells may be due to its higher DNA binding ability and efficient 
delivery to the cancer cells as compared to carboplatin. 
 
                                                          
‡
 Reproduced in part with permission from Adamantane-Platinum Conjugate Hosted in β-
Cyclodextrin: Enhancing Transport and Cytotoxicity by Noncovalent Modification. Deepali 
Prashar, Yi Shi, Debjyoti Bandyopadhyay, James C. Dabrowiak and Yan-Yeung Luk* Bioorg. 
Med. Chem. Lett. 2011, 21, 7421-7425. 
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4.1 Background and Significance 
4.1.1 Why Beta-Cyclodextrin (βCD)? 
Cyclodextrins (CD) have been known to prevent aggregation during protein refolding.
46-47, 53  
The hydrophobic core of CD is employed for forming molecular inclusion complexes with a 
wide range of hydrophobic small molecules or drugs.
52, 152
 The ability of CD to allocate 
hydrophobic drug molecules in its hydrophobic cavity helps in increasing the stability, solubility 
and bioavailability of such drugs.
153-154 
Furthermore, the primary and secondary hydroxyl groups 
of CD are potential sites for chemical modification for conjugating targeting ligands or 
antibodies to achieve targeted drug delivery. Anticancer drugs such as cis-platin, carboplatin and 
oxaliplatin lack target specificity. The dose-limiting side effects and intrinsic or acquired 
resistance are the main draw backs associated with these drugs. Targeted drug delivery is 
important for conventional chemotherapy and for preventing the normal tissue from the toxic 
effects of the drug. Target specificity can be achieved by either employing antigen-antibody 
interactions or targeting ligands.  To exploit cyclodextrins as targetable drug delivery systems, 
they can be functionalized with targeting moieties such as peptides, hormones, antibodies and 
carbohydrates. There are a number of antibodies/ligands, which are capable of recognizing 
specific antigens/receptors on the tumor cells. Furthermore, a large number of cancer cells over 
express surface receptors for folic acid
155-158
 and galactose.
159-160 
 
4.1.2 Platinum compounds as anticancer agents 
Platinum-based compounds are an important class of active chemotherapeutic agents for 
treating various cancers; 
161-164
  yet the mechanism of drug action are still unraveling.
165-167
  
Dabrowiak and coworkers have reported that for cisplatin and carboplatin, a platinum carbonato 
complex rather than the reactive mono-aquo complex may be responsible for cytotoxic effects in 
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cells.
168-169
 With this growing understanding, the development and optimization of the 
pharmaceutical properties of platinum-based therapeutic agents has been largely empirical.
170-171
 
This work presents a strategy for noncovalent modification via host-guest chemistry to enhance 
the cytotoxicity of a dicarboxylate chelated platinum (II) complex, which is an analog of the 
clinically used drug carboplatin. This noncovalent modification strategy employed the cyclic 
sugar β-cyclodextrin (βCD) to encapsulate an adamantane-derivatized diacarboxylate complexed 
with a platinum (II) ion.  
4.1.3 β-cyclodextrin as drug carrier 
Noncovalent modification of active agents provides an alternative approach to achieve desired 
properties for drug development, such as increased water-solubility, cellular uptake and targeted 
delivery, without severely tampering the activity of the compounds.  Kim and coworkers have 
demonstrated the encapsulation of the anti-cancer drug oxaliplatin in the hydrophobic cavity of 
cucurbit. Preliminary results indicated that the activity of oxaliplatin decreased after 
encapsulation in cucurbit.
172
 Brabec and coworkers have studied the cytotoxicity, mutagenicity, 
cellular uptake and DNA interactions of trans-platinum complexes tethered to 1-
adamantylamine.
171
 Cyclodextrins are used in pharmaceutical applications for improving drug 
properties such as enhancing the solubility, stability and bioavailability of drugs.
52, 153, 173
 
Interestingly, Maxfield and coworkers discovered that β-cyclodextrin (βCD) has a high 
propensity to be taken into mammalian cells presumably through pinocytosis.
174
 This discovery 
promoted us to explore the possibility of enhancing the properties of a platinum (II)-based 
compound by noncovalent encapsulation in βCD. I synthesized an adamantane-dicarboxylate 
chelated with a platinum (II) ion, and used βCD to form a host-guest complex with the 
adamantane moiety of the chelate (Scheme 4.1). The binding is stoichiometric in water with one 
144 
 
 
 
adamantane group being hosted in the hydrophobic annular cavity of a single βCD. The 
cytotoxicity of this host-guest complex was tested against neuroblastoma cells and compared to 
the cytotoxicity of carboplatin. Proteins such as antibodies can be conjugated to cyclodextrin to 
achieve reduced aggregation of proteins
128
 and/or targeted drug delivery. This approach provides 
both chemical versatility for structural modification and potential for protein-drug conjugate 
therapeutics. 
4.2 Results and Discussion 
4.2.1 Synthesis of the βCD adamantane-platinum host-guest complex (6) 
Scheme 4.1 Synthesis of the βCD adamantane-platinum host-guest complex (6) 
 
 
 
Scheme 4.1 shows the synthesis of the βCD adamantane-platinum host-guest complex (6). 
Briefly, tosylation of adamantane alcohol (1), 
175
 afforded the tosylate (2). Displacement of tosyl 
group in (2) with diethylmalonate gave the diethyl ester (3), which on hydrolysis provided the 
diacid (4). The detailed synthesis of compound 4 has been reported elsewhere.
176-177
 I noted that 
direct coupling of (4) and cis [Pt(NH3)2(H2O)]
+2
 (5),
178-179 
gave a grey solid that was insoluble in 
all solvents studied (Scheme 4.2).  
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Scheme 4.2 Synthesis of cis [Pt(NH3)2(H2O)2]
+2
 (5) and conjugation of compound 5 to 
adamantane carboxylic acid (4) 
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Because cyclodextrins are known to form water soluble inclusion complexes with hydrophobic 
groups,
52
 I tried using  βCD to possibly extract the product from the insoluble grey solid into 
water. However, addition of βCD to an aqueous suspension of the grey solid did not result in 
detectable product. Interestingly, treating the diacid (4) first with 1 equivalent of βCD, followed 
by addition of [Pt(NH3)2(H2O)2]
+2
 (5), resulted in the desired water-soluble conjugate (6). The 
details of the synthesis suggest that the exchange rate of the βCD-adamantane host-guest 
complex is likely slow, and that using βCD likely provides a general approach to render 
hydrophobic small molecules soluble in water. [
1
H, 
15
N] Heteronuclear single quantum 
coherence (HSQC) NMR was taken for the βCD adamantane-platinum host-guest complex 
(Figure 4.1). The chemical shift (δ) in HSQC for 1H= 4.13 and 15N = -82.0, was similar to that 
observed for carboplatin.
179
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Figure 4.1 [
1
H, 
15N] HSQC NMR of βCD adamantane carboplatin analog host-guest complex 
(6) in 5% D2O/H2O: δ (ppm) 
1H = 4.13, δ 15N = -82.0. 
4.2.2 Studying cytotoxicity of host-guest complex (6) and carboplatin using colorimetric assay 
The βCD adamantane-platinum host-guest complex (6) is structurally close to carboplatin 
because of the common dicarboxylate motif. To explore the therapeutic potential of the host-
guest complex (6), I compared cytotoxicity of 6 and carboplatin,
169
 towards neuroblastoma cells 
(SK-N-SH). The neuroblastoma (SK-N-SH) cells were grown for 24 h in 96-well plates, 
followed by treating the cells with different concentrations of 6 or carboplatin. After 1 h 
incubation, medium containing 6 or carboplatin was replaced with fresh culture medium. The 
cells were allowed to grow over a period of  24 h, 48 h, and 72 h (recovery period) in different 
96-well plates. At the end of each recovery period, the number of live cells was determined by a 
colorimetric cell counting assay (CCK-8).
180
 The assay utilizes a water soluble tetrazolium salt, 
which is reduced by dehydrogenases in the live cells to give a yellow colored product (formazan) 
(Scheme 4.3). The amount of the formazan dye produced in the culture medium is directly 
proportional to the number of living cells.  
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Scheme 4.3 Reduction of WST-8 by dehydrogenases to produce yellow colored dye formazan 
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The survival (%) was calculated by using the equation (OD450 sample)/(OD450 control) ×100, 
where the sample OD was obtained from the cells treated with 6 or carboplatin, and the control 
OD was obtained from cells alone.
181
 Figure 4.2 shows the plots of survival (%) of 
neuroblastoma (SK-N-SH) cells as the concentrations of 6 and carboplatin increases at different 
recovery periods of 0 h, 24 h, 48 h, and 72 h (starting immediately after host-guest complex (6) 
or carboplatin were replaced by fresh culture medium). Immediately after 1 h of culturing the 
cells with 6 or carboplatin (zero recovery time), the number of viable cells remained high. 
However, for longer recovery time, the cells exhibited an unusual dose dependent behavior to 
carboplatin. The cytotoxicity of carboplatin increases in the drug concentration range 0 µM to 
~500 µM, reaches a maximum at ~500 µM and decreases in the range, 500 µM to 1000 µM 
(Figure 4.2 A).  
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Figure 4.2 Plots of survival (%) of SK-N-SH cell treated with (A) carboplatin, and (B) 6, as a 
function of concentration with different recovery times at 0 h, 24 h, 48 h and 72 h. 
Recently, it was shown that carboplatin exists in a monomer-dimer equilibrium in aqueous 
solution, and there is evidence that the same equilibrium may also exist in culture media.
182
 
Since the concentration of a species in monomer-dimer equilibrium is dependent on the total 
concentration of the agent in the medium, it is possible that the reduced cytotoxicity of 
carboplatin at high concentration is due to the presence of dimers, which may be less toxic to the 
cells than the monomeric form of the drug. While being non-toxic at all concentrations for a 
recovery time of 0 h, 6 exhibited the typical dose-response expected at longer recovery times 
with the longest recovery time (72 h) producing the greatest amount of cell death. Comparison of 
the survival (%) for 6 with carboplatin indicates that overall 6 is more toxic to the neuroblastoma 
cells than is carboplatin. 
4.2.3 Cytotoxicity of host-guest complex (6) and carboplatin against SK-N-SH cells increases 
with increasing incubation times 
It is intriguing that increasing the concentration of carboplatin did not strictly lead to increase 
in cytotoxicity. The effect of different incubation times of 6 and carboplatin on neuroblastoma 
cells (SK-N-SH) was also examined. Confluent layers of SK-N-SH cells were incubated with 
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500 µM of each agent for 2 h, 4 h, 6 h, 8 h and 12 h in 96-well plates. After each incubation 
time, medium containing 6 or carboplatin was replaced with fresh culture medium, and the 
number of live cells was immediately determined by CCK-8 assay (recovery time = zero). 
 
Figure 4.3 Survival (%) of SK-N-SH cells when treated with 500 µM carboplatin and 6 at 
different incubation times of 2 h, 4 h, 6 h, 8 h, and 12 h. The recovery period was 0 h for all 
incubation times tested.  
Figure 4.3 shows that exposure of the neuroblastoma cells to both carboplatin and 6 for for 
exposure times up to 12 h enhanced the cytotoxic effects of both agents but compound 6 was 
clearly more toxic than carboplatin. After about 6 h of incubation of the SK-N-SH cells with 500 
µM of 6 or carboplatin, I observed 87.04 ± 4.69% survival of SK-N-SH cells treated with 6, and 
almost no decrease in the survival of SK-N-SH cells treated with carboplatin. Carboplatin 
appeared to begin showing significant cytotoxic effects (recovery period = 0), only after cells 
were incubated for about 6 h in the presence of the drug. After 12 h of incubation, 66.29 ± 3.20% 
and 82.53 ± 3.61% survival was observed for cells treated with 6 and carboplatin respectively.  
These results indicate that increasing the incubation time of the cells with carboplatin results in 
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an increase in the cytotoxic effects of the agents. However, higher cytotoxic effect of 6 over 
carboplatin is evident at longer incubation times (6 h-12 h) of the cells with the agents. 
4.2.4 Cyclodextrin enters cells through pinocytosis 
Maxfield and coworkers recently discovered that endocytosis of βCD is responsible for 
cholesterol reduction in Niemann-Pick type C mutant cells.
174
 This effect is believed to be due to 
the internalization of cyclodextrin in the cell through fluid phase pinocytosis.
174, 183-184
 
Pinocytosis is a form of endocytosis in which surrounding fluids and small particles are brought 
into the cell suspended within small vesicles, which subsequently fuse with lysosomes. To 
validate the internalization of βCD, I synthesized fluorescein isothiocynate (FITC) tagged 
cyclodextrin by literature reported procedures (Scheme 4.4).
185
   
Scheme 4.4 Synthesis of FITC tagged βCD (10) 
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SK-N-SH cells were treated with FITC or FITC-tagged βCD (10). Confocal fluorescence 
images showed that SK-N-SH cells treated with compound 10 or FITC alone exhibited green 
fluorescence (Figure 4.4), suggesting that both are efficiently internalized into the SK-N-SH cells 
post fixation. Interestingly, compound 10 appeared to be localized around the nucleus of the 
cells, whereas FITC alone stained the entire cell.  
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Figure 4.4 Confocal fluorescence image of SK-N-SH cells incubated with (A) 150 nM of FITC-
tagged βCD and (B) FITC alone. The cells were fixed with 4% paraformaldehye before viewing 
under the microscope. Scale bar = 76 µm. 
4.2.5 SDS-PAGE confirms host-guest complex (6) binds DNA more than carboplatin 
Because binding to DNA is a key element for platinum-based therapeutic agents,
186
 I 
examined and compared the binding of a plasmid DNA (pBR322) by 6 and by carboplatin using 
agarose gel electrophoresis. Plasmid DNA (pBR322) exists in different conformations (Form I 
and Form II), each having a different mobility in an agarose gel. Form I DNA is a circular 
supercoiled DNA, and Form II DNA is a nicked circular DNA. Form I DNA is wound into a 
compact structure and hence is the fastest moving conformation of the plasmid. Once the 
plasmid DNA is treated with the platinum agents, binding and unwinding of Form I DNA takes 
place, which is manifested by a decrease in the mobility of Form I DNA.
187-189
 The plasmid DNA 
was incubated for 24 h with different concentrations (30 µM to 100 µM) of 6 or carboplatin. The 
agarose gel image (Figure 4.5) shows that the mobility of DNA decreased with increase in 
concentrations of 6 and carboplatin. This decrease in the DNA mobility in the agarose gel is 
consistent with the unwinding of Form I DNA due to binding of 6 or carboplatin. This result 
suggests that 6 binds to and unwinds plasmid DNA (pBR322) more than carboplatin. For 
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example, the DNA in lane 11 (6 at 100 µM) migrated less than in lane 18 (carboplatin at 100 
µM). As shown in Figure 4.5, carboplatin and 6 have little effect on the mobility of the nicked 
circular, Form II DNA (no supercoiling) in the gel.   
 
Figure 4.5 Agarose gel electrophoresis image of plasmid DNA (pBR322) (33.3 µM base pairs) 
after incubation with 6 or carboplatin in 10 mM HEPES, pH 7.4 for 24 h. Lanes 2 through 11 
contained 30, 35, 40, 45, 50, 60, 70, 80, 90, and 100 µM of 6, and lanes 12 through 18 contained 
30, 40, 50, 70, 80, 90 and 100 µM of carboplatin, respectively. Lane 1 (control) contained only 
plasmid DNA (pBR322). This study was done in conjunction with Yi Shi from Professor 
Dabrowiak’s lab. 
4.2.6 βCD alone does not bind DNA 
The potential interaction between βCD and DNA using agarose gel electrophoresis was also 
studied. The concentrations of βCD used for the DNA interaction studies were same as those 
used for studying the binding of 6 to pBR322 DNA. No unwinding of supercoiled Form I closed 
circular DNA was observed for all concentration of βCD used for the study (Figure 4.6). This 
suggests that either βCD binds DNA but does not affect the mobility of Form I or Form II DNA 
or βCD does not bind DNA at all. From these results, it is concluded that the decrease in of 
mobility of DNA on treatment with 6 is only due to the binding of the platinum to DNA. 
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Figure 4.6 Agarose gel electrophoresis image of plasmid DNA (pBR322) (33.3 µM base pairs) 
after incubation with βCD in 10 mM HEPES, pH 7.4 for 24 h. Lanes 2 through 12 contained 30, 
35, 40, 45, 50, 60, 70, 80, 90, and 100 µM of βCD respectively. Lane 1 (control) contained only 
pBR322 DNA. This study was done in conjunction with Yi Shi from Professor Dabrowiak’s lab. 
4.2.7 Platinum uptake studies using ICP-MS 
Because 6 appears to be more cytotoxic than carboplatin for SK-N-SH cells, I examined if the 
uptake rate of the chemical agents by the SK-N-SH cells possibly contributes to the observed 
difference in the cytotoxicity. I used inductively coupled plasma mass spectrometry (ICP-MS) to 
directly measure the platinum content by SK-N-SH cells over time.
169, 190
 Figure 4.7 shows the 
plots for platinum uptake per cell, in attomoles (10
-18
) as a function of incubation time. Six well 
plates with each well containing 3.5 ×10
5 
SK-N-SH
 
cells suspended in culture medium, were 
allowed to adhere on the well surface for 24 h. The number of viable cells in the wells was 
measured by light microscopy using a heamocytometer and trypan blue. The cells in the wells 
were then treated with 500 µM of 6 or carboplatin for different incubation times (0, 1, 2, 3, and 4 
h). The cells were trypsinized and pelleted by centrifugation and the pellets were washed with 
phosphate buffered saline (PBS, 10 mM) twice. The cells were then lysed in 70% nitric acid at 
50 °C for 48 h and the analyzed for the amount of platinum by ICP-MS. The uptake rate of 
platinum per cell, in attomoles (10
-18
) per hour per cell, was calculated from the slope of the plot 
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of amount of platinum per cell versus the incubation time (Figure 4.7). The uptake rates of 
carboplatin and 6 at 500 µM by SK-N-SH cells were found to be 16.0 ± 0.56 and 64.9 ± 1.5 amol 
of Ptcell
-1
h
-1
 respectively. Comparing the uptake of platinum (Figure 4.7) and the survival (%) of 
SK-N-SH cells (Figure 4.2) after 4 h incubation, while the uptake of carboplatin was ~ 4.4 times 
higher than that of 6, there was a decrease of  ~ 6% in the survival for  SK-N-SH treated with 6 
but no observable decrease of survival for cells treated with carboplatin. 
 
 
Figure 4.7 Platinum (amol) taken up per SK-N-SH cell, when exposed to carboplatin (500 µM) 
and 6 (500 µM) as a function of time. The rate of uptake (amol of Pt cell
-1 
h
-1
) was found to be 
16.0 ± 0.56 and 64.9 ± 1.4 for cells treated with 6 and carboplatin, respectively. 
These data indicate that the uptake rate of carboplatin is ~ 4 times higher than 6, while the 
cytotoxicity experiments suggest that 6 is more cytotoxic than carboplatin. This result is 
surprising and suggests that the cytotoxic effects of chemical agents are complex. Hence, the 
amount of platinum entering the cell alone cannot be the basis for the different cytotoxic effects 
of the compounds. However, since the main target for the platinum agents is believed to be 
DNA, carboplatin could be more susceptible to reaction with and inactivation by components in 
the cytosol than 6.  
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4.2.8 Achieving targeted drug delivery 
Many systems have been developed for selective delivery of drugs to their site of action by 
grafting biorecognizable carbohydrate antennae on to the carrier.
191
 Pack and coworkers have 
synthesized cyclodextrin-ployethylenimine conjugates for targeted in-vitro gene delivery.
192
 
Shinoda and coworkers have investigated the specific interaction between galactose branched-
cyclodextrins and hepatocytes in-vitro.
193
 Davis and coworkers have synthesized transferrin-
PEG-adamantane conjugate for nanoparticle modification. The transferrin-modified 
nanoparticles were further used for tumor targeted gene delivery.
194
  
The capacity and specificity of the drug carrying cyclodextrin can be increased by attaching 
bio-recognizable galactose ligands. Attachment of multiple cyclodextrins carrying the drug will 
also increase the net amount of platinum reaching the tumor environment and will hence 
decrease the amount of platinum being used (Figure 4.8). The galactosyl-β-cyclodextrin 
derivatives can be recognized by galactose binding proteins called galectins.
195
 The recognition 
is dependent upon the length of the spacer chain between the cyclodextrin and the sugar head 
group and also on the number of sugars presented to the lectin.
196
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Figure 4.8 Interaction between directing ligands (antibody, folic acid and galactose) and cancer 
cell surface receptors (antigen, folic acid receptor and galactose receptor). 
Scheme 4.5 Conjugation of compound 14 with cyclodextrin-galactose conjugate (15) 
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Since 6 was soluble in water, I attempted the synthesis of a cyclodextrin-galactose conjugate 
(Scheme 4.5) with the aim of achieving target specificity. The synthesis of the galactose head 
group connected with a βCD with a spacer chain length of five carbons was tried (Scheme 4.3). 
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Briefly, compound 14 was synthesized using-literature reported procedures.
88-89
 Compound 17 
was synthesized by treating compound 16 with sodium azide in DMF. Reduction of compound 
17 with Pd/C in ethanol gave compound 18. Compound 18 was condensed with mono-methyl 
nonanoic acid in the presence of triethyl amine to yield compound 19. Complete ester hydrolysis 
of 19 was achieved with methanolic sodium hydroxide to afford compound 20. Compound 14 
was condensed with compound 20 using DCC/HOBt to obtain compound 15, however pure 
product was not obtained (Scheme 4.6). Although the 
1
H NMR for the compound 15 was not 
pure, HRMS confirmed product formation. 
Scheme 4.6 Synthesis of cyclodextrin-galactose conjugate (15) 
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4.3 Conclusion and Perspectives 
This work reports the synthesis and development of a βCD encapsulated adamantane-platinum 
conjugate (6). Conjugate 6 exhibited higher cytotoxicity than carboplatin towards neuroblastoma 
cells. The uptake of βCD adamantane-platinum inclusion complex is believed to be due to the 
internalization of βCD through pinocytosis. Agarose gel electrophoresis confirmed the binding of 
6 to pBR322 DNA, where 6 exhibited a higher level of binding to DNA than carboplatin. As gel 
electrophoresis confirmed the binding of 6 to pBR322 DNA, this work suggests that noncovalent 
modification of a therapeutic agent can be a powerful strategy to control the binding activities 
and other pharmaco-properties of the therapeutic agent. Interestingly, the ICP-MS measurement 
indicated that carboplatin had a higher uptake rate than 6 into the cells. These results suggest that 
other factors such as target receptor binding and heterogeneous distributions of agents inside the 
cells likely play more important roles than mere cellular uptake for cytotoxic effects. The 
formulation and structural design for controlling drug activity can be studied and integrated by 
noncovalent modification of the drug candidates, rather than studied as separate topics.  
Two approaches can be used to achieve targeted dug delivery. The first approach involves 
conjugation of multiple copies of ligands such galactose and folic acid with βCD. The βCD can 
in turn be used to carry multiple copies of candidates like 6 or other drugs, to achieve 
combination chemotherapy. The second approach involves conjugation of βCD with antibodies, 
peptide or protein drugs which are recognized by membrane proteins of cancer cell to achieve 
targeted drug delivery. Covalent modification of proteins like lysozyme and RNase A with βCD 
have been reported to prevent aggregation, surface adsorption and to increase the thermal 
stability of the modified proteins significantly (Chapter 2). Hence conjugation of βCD with 
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antibodies can help prevent aggregation of the antibodies and ensure efficient delivery of drugs 
to the affected site.  
4.4 Experimental Section 
Materials and Methods 
Chemicals. Carboplatin was obtained from Sigma-Aldrich (Milwaukee, WI). A stock solution 
of carboplatin (10 mg/mL, 26 mM) was prepared in water before use. Culture medium, minimum 
essential medium with Earle’s salts and L-glutamine (EMEM) (10-010) was obtained from 
Mediatech (Herndon, VA). Cell counting kit 8 (CCK-8) was purchased from Dojindo Molecular 
Technologies, Inc. (Gaithersburg, MD). For the DNA cleavage studies, HEPES, agarose, Trizma 
base, boric acid, EDTA, and ascorbic acid were purchased from Sigma-Aldrich (St. Louis, MO), 
and the plasmid DNA (pBR322), 25 μg/μL, was obtained from Invitrogen (Carlsbad, CA). All 
other chemicals were obtained from Aldrich Chemicals (Milwaukee, WI). Water used for 
preparing all buffers and solutions had resistivity of 18 MΩ cm (Millipore, Billerica, MA). 
CCK-8 Cytotoxicity Assay 
All Cell studies were carried out under standard conditions in a humidified, 37 °C, 5% CO2 
atmosphere. Human neuroblastoma (SK-N-SH) cells in culture medium (EMEM + 10% FBS, 
100 μg/mL streptomycin, 100 IU/mL penicillin, and 2.0 mM L-glutamine) were plated in 96-well 
plates (costar, tissue culture treated, Corning Incorporated, Corning NY), with each well 
containing 100 µL of cell solution with a concentration of 5×10
4 
cells/mL. The viabilities of SK-
N-SH, determined with a hemacytometer under standard trypan blue conditions. After being 
plated, the SK-N-SH, were given 24 h to adhere to the bottom of the wells. Each plate consisted 
of six wells containing medium without cells, six wells containing medium with cells, and the 
remaining wells containing cells with medium and different concentrations of 6 or carboplatin. 
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After 1 h, the drug-containing medium was removed and the cells were washed twice with fresh 
culture medium. The cells were then allowed to recover for 24, 48 and 72 h (recovery period), 
after which the number of live cells was determined by the colorimetric cell counting assay 
(CCK 8 assay).
180
 The assay utilizes a water-soluble tetrazolium salt, which is reduced by 
dehydrogenases in the live cells to give a yellow colored product (formazan). After 2 h of 
incubation of the cells with the water soluble tetrazolium salt, the amount of the formazan dye 
produced in the culture medium is directly proportional to the number of living cells. The 
number of live cells in the wells was determined by measuring the absorbance of the medium in 
the wells at 450 nm on ELx 800 absorbance microplate reader from BioTek (Highland Park, 
Winooski, VA). The survival (%) was calculated using the equation (OD450 sample)/(OD450 
control) ×100, where the sample OD was obtained from the cells treated with host-guest complex 
6 or carboplatin, and the control OD was obtained from cells without any chemical treatment. 
Cleaning of Microscope Cover Glass 
 Fisherbrand microscope cover glasses (Fisher Scientific, Pittsburgh, PA), were cleaned with 
piranha solution prior to cell experiments. The cover glasses were soaked in piranha solution (3 
parts of 35% H2O2 in water and 7 parts of concentrated H2SO4) at 70 °C for 45 min. 
Warning! Piranha solution is extremely corrosive and has the potential for detonation if 
contaminated with a significant amount of oxidizable material. After cooling, the piranha 
solution was poured off and the slides were rinsed 20 times with water having a resistivity of 18 
MΩ cm. 
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Confocal Laser Scanning Microscopy (CLSM) 
  Piranha cleaned cover glasses in a six-well plate were incubated with 1% of SK-N-SH cells in 
culture medium (EMEM + 10% FBS, 100 μg/mL streptomycin, 100 IU/mL penicillin, and 2.0 
mM L-glutamine). The cells were allowed to adhere on the cover glass for 24 h. The adhered 
cells on the cover glass were then treated with 150 nM solution of βCD-FITC in DMSO for 24 h. 
The cover glass was then washed thoroughly with 10 mM phosphate buffered saline (PBS, 2.7 
mM potassium chloride, 137 mM sodium chloride, 8 mM sodium phosphate dibasic, 1.48 mM 
potassium phosphate monobasic), pH 7.4. The cells were fixed with 4% paraformaldehye 
prepared in 10 mM PBS, for 15 min and the attached cells were again rinsed with 10 mM PBS, 
before viewing under the microscope. Confocal fluorescence images of neuroblastoma cells (SK-
N-SH) treated with FITC-tagged βCD were taken on Carl Zeiss MicroImaging GmbH 
(Gottingen, Germany).  
Platinum Uptake Study by SK-N-SH Cells Treated with βCD adamantane Carboplatin 
Analog Inclusion Complex (6) and Carboplatin Using ICP-MS 
 Two six-well plates (plate 1 and plate 2) with each well containing 3.5 ×10
5 of SK-N-SH
 
cells 
suspended in culture medium  (EMEM + 10% FBS, 100 μg/mL streptomycin, 100 IU/mL 
penicillin, and 2.0 mM L-glutamine) were allowed to adhere on the well surface for 24 h. The 
number of viable cells in each well for plate 1 and plate 2 after 24 h was found to be 2.04 ×10
5 
and 3.85×10
5 
respectively. The cells in the wells were then treated with 500 µM of 6 or 
carboplatin for different incubation times (0, 1, 2, 3, and 4 h). The cells were trypsinised using 1 
mL 0.25% trypsin/0.5 mM EDTA solution after being treated with 6 or carboplatin. The 
suspended cells were then pelleted by centrifugation for 5 min at 3000 rpm in a 15 mL centrifuge 
tube. After centrifugation, culture medium was removed and the cells were resuspended in 2 mL 
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of 10 mM PBS and transferred into 1 mL eppendorf tubes. The cells were pelleted a second time 
by centrifugation, PBS was removed and the cells were lysed for 48 h at 50 °C in 0.5 mL of 70% 
nitric acid. The nitric acid solutions of the cell lysate were analyzed for amount of platinum by 
inductively coupled plasma mass spectrometry (ICP-MS) (Department of Engineering, Syracuse 
University). The uptake rate of platinum per cell, in attomoles (10
-18
) per hour, was calculated 
from the total number of viable cells (number of viable cells in each well in the six well plates, 
before treatment with 6 and carboplatin were 2.04 ×10
5 
and 3.85×10
5 
respectively as noted 
above) and the number of moles of platinum that each cell took up from the culture medium per 
hour. 169 
Agarose Gel Electrophoresis 
 The  agarose gel was prepared by dissolving 1 g of agrose in 100 mL of 0.5 × Tris borate EDTA 
buffer (0.045 M Tris borate buffer and 0.001 M EDTA). Different concentration of 6 (30 µM to 
100 µM ) and carboplatin (30 µM to 100 µM) were mixed 10 mM HEPES buffer (pH 7.4), 
plasmid DNA (pBR322, 33.0 μM base pairs) and the volume was made up to 20 µL with 
distilled water. The samples were heated at 37 °C for 24 h. The solutions of 6 or carboplatin or 
βCD (20 µL) were further mixed with 2.5 µL of bromophenol blue and 8 µL of each sample was 
then loaded on to the gel. Electrophoresis was performed at 100 V for 4 h. The gel was then 
stained with ethidium bromide for 30 min. The gel was destained in water for 15 min and was 
viewed under UV light using Kodak Gel Logic 100 equipped with Fisher Biotech IT-88A 
transilluminator. 
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Synthetic Procedures and Spectral Data 
Synthesis of compound 9 
 
 
To an aqueous solution of potassium tetrachloroplatinate (II) (0.005g, 1.20 mmol) was added 
potassium iodide (0.799 g, 4.81 mmol) and stirred at rt for 30 min. When the solution became 
dark brown in color, 
15
NH4Cl (0.131 g, 2.40 mmol) was added and the pH was adjusted to 11.0 
using 10M KOH solution. The reaction mixture was stirred at room temperature for 1 h. 
Reaction mixture was filtered to obtain compound 9 as a yellow solid (0.489 g, 84%). [
1
H, 
15
N] 
HSQC NMR (500 MHz, 5% D2O in water): δ (
1H) = 3.93, δ (15N) = -52.0. 
Synthesis of compound 5 
Pt
H3
15N
H3
15N
H2O
H2O
5  
To a suspension of compound 9 (0.042g, 0.087 mmol) in water added silver nitrate (0.029 g, 
0.175 mmol) and stirred the reaction in dark for 20 h. Filtered the reaction mixture to remove 
silver iodide to yield compound 5 (quantitative) as a colorless liquid. [
1
H, 
15
N] HSQC NMR (500 
MHz, 5% D2O in water): δ (
1H) = 4.50, δ (15N) = -86.5. 
 
 
 
Pt
H3
15N
H3
15N
I
I
9
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Synthesis of compound 6 
O O
O O
O
Pt15NH3
15NH3
6
 
Compound 4 (0.029 g, 0.008 mmol) was dissolved in a mixture of methanol and water (1:3). 
βCD (0.099 g, 0.008 mmol) was added to the dissolved solution and the reaction mixture was 
stirred at rt for 1.5 h. A solution of compound 5 (0.387 mmol in 2 mL of water) was added 
dropwise to the above solution and the reaction mixture was stirred at rt for 3.5 h. The reaction 
mixture was freeze dried to obtain the crude product as a white solid. The white solid was then 
suspended in hot water and allowed to precipitate out completely at rt. The supernatant was 
discarded by decantation to obtain compound 6 (0.122 g, 95%) as white solid. 
1
H NMR (300 
MHz, D2O): δ 5.10-5.08 (m, 7H), 3.90-3.80 (m, 26H), 3.64-3.61 (m, 16H), 3.58-3.56 (br s, 2H), 
2.98 (br s, 2H), 2.50 (br s, 1H), 2.1 (br s, 3H), 1.92-1.88 (m, 3H), 1.78-1.74 (m, 4H), 1.60 (s, 
9H), 1.43 (br s, 3H), 1.32 (br s, 1H). [
1
H, 
15
N] HSQC NMR (500 MHz, 5% D2O in water): δ (
1
H) 
= 4.13, δ (15N) = -82.0. HRMS found = 873.7782 [M +2+2Na] +/2, calcd for [C12H18O6+2+2Na] 
+ 
/2 = 873.7769. 
Synthesis of  compound 12 
OTs
12  
Dissolved compound 11 (2.54 g, 0.002 mmol) in 57 mL of water by heating the reaction mixture 
to 60 °C with vigorous stirring. Reaction mixture was cooled to rt. To the resulting suspension 
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added finely powered 1-(p-tolunenesulfonyl) imidazole (2.0 g, 0.009 mmol). Reaction mixture 
was stirred at rt for 2 h. A solution of sodium hydroxide (1.15 g, 0.028 mmol) in 3 mL water was 
added slowly over a period of 5 min. Reaction mixture was stirred at rt for 10 min and filtered to 
remove unreacted 1-(p-tolunenesulfonyl) imidazole. Reaction mixture was quenched by addition 
of ammonium chloride (3.08 g, 0.057 mmol). The reaction mixture was concentrated to half its 
volume by air blowing overnight. Compound 12 was obtained as white solid (1.138 g, 39%) 
which was filtered and washed with ice-cold water and acetone.
 1H NMR (300 MHz, DMSO): δ  
7.73 (d, JH-H = 8.1, 2H), 7.42 (d, JH-H =8.1, 2H), 5.62-5.83 (m, 14H), 4.83 (br s, 4H), 4.51 (br s, 
2H), 4.44-4.57 (m, 2H), 4.30-4.38 (m, 2H), 4.15-4.20 (m, 1H), 3.20-3.65 (m, 40H), 2.49 (s, 3H). 
13C NMR (75 MHz, DMSO): δ 145.3, 133.5, 130.5, 128.2, 102.5, 82.3, 82.1, 82.0, 73.6, 73.0, 
72.6, 60.5, 21.8. HRMS found 1311.3673 = [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
=1311.3678. 
Synthesis of compound 13 
N3
13  
Dissolved compound 12 (0.200 g, 0.155 mmol) and sodium azide (0.151 g, 0.002 mmol) in water 
(1 mL) and stirred reaction mixture at 80 °C for 3 d. Added acetone (10 mL) to precipitate a 
white solid, which was redissolved in water (10 ml) and reprecipitated with acetone. Repeated 
this process to obtain compound 13 as a white solid (0.151 g, 84%).
1
H NMR (300 MHz, 
DMSO): δ 5.71-5.65 (m, 14H), 4.81 (br s, 5H), 4.44-4.40 (m, 6H), 3.62-3.29 (m, 40H). 13C NMR 
(75 MHz, DMSO): δ 102.9, 102.5, 102.2, 82.4, 82.1, 82.0, 73.6, 73.4, 73.0, 72.8, 72.6, 60.5. 
HRMS found = 1134.3937 [M + Na]
 +,
 calcd for [C12H18O6+Na] 
+ 
=1134. 3930. 
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Synthesis of compound 14 
NH2
14  
Dissolved compound 13 (0.044 g, 0.037 mmol) in 0.5 mL DMF. Added triphenyl  phosphine 
(0.109 g, 0.415 mmol) to the reaction mixture and stirred reaction mixture at rt for 2 h. Added 
0.1 ml deionized water and refluxed the solution for 30 min. Cooled reaction mixture to rt and 
precipitated in acetone to obtain compound 14 (0.032 g, 76%) as white solid.
 1
H NMR (300 
MHz, DMSO): 3.34 (m, 30H), 3.56-3.65 (m, 14H), 4.43-4.46 (m, 6H), 4.83 (d, J H-H =2.0, 6H), 
4.89 (d, J H-H =2.0, 1H), 5.61-5.77 (m, 14H).
 13
C NMR (75 MHz, DMSO): δ 101.9, 82.8, 81.6, 
81.5, 73.0, 72.4, 72.0, 59.9, 41.7. HRMS found = 1182.3640 [M + Na]
 +,
 calcd for 
[C12H18O6+Na] 
+ 
= 1182.3654. 
Synthesis of compound 17 
O
N3
OAc
OAc
OAc
AcO
17  
Sodium azide (0.352 g, 5.41 mmol) was added to compound 16 (0.300 g, 0.729 mmol) in 
anhydrous DMF (7 mL) and the reaction mixture was heated at 80 ºC for 6 h. The reaction 
mixture was suspended in brine and extracted with DCM. Solvent was evaporated and the 
residue was dried under vacuum to yield compound 17 (0.189 g, 70%) as a white solid. Rf = 0.41 
(50% EtOAc in Hexane).
1
H NMR (300 MHz, CDCl3): δ 5.41-5.40 (m, 1H), 5.18-5.11 (m, 1H), 
5.029 (dd, JH-H = 10.3, JH-H = 8.6, 1H), 4.58 (d, 1H), 4.16-4.13 (m, 2H), 4.02-3.97 (m, 1H), 2.15 
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(s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 1.97 (m, 3H).
  
 170.3, 170.1, 169.9, 169.3, 88.1, 72.7, 70.6, 
68.0, 67.2, 66.9, 61.2, 20.6, 20.5, 20.5, 20.4. HRMS found = 396.1007 [M + Na]
 +,
 calcd for 
[C12H18O6+Na] 
+ 
= 396.1013. 
Synthesis of compound 18 
O
NH2
OAc
OAc
OAc
AcO
18  
Compound 17 (0.189 g, 0.507 mmol) was dissolved in ethanol (20 mL) and added catalytic 
amount of Pd/C (15.0 mg, 50% wet with water, unreduced 10% Pd) to it. The compound was 
hydrogenated at rt for 3.5 h. Pd/C was removed by filtration through a pad of silica and the 
solvent was evaporated. Residue was dried under vaccum to yield compound 18 in quantitative 
yield as a white solid. Rf = 0.55 (90% DCM in MeOH).
1
H NMR (300 MHz, CDCl3): δ 5.38-5.37 
(br m, 1H), 5.02-5.00 (m, 2H), 4.14 (d, JH-H = 8.25, 1H), 4.15-4.06 (m, 2H), 3.90-3.85 (m, 1H), 
2.13 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H).
 13
C NMR (75 MHz, CDCl3): δ 170.4, 170.2, 
170.0, 85.2, 71.3, 71.2, 69.7, 67.6, 61.7, 20.9, 20.7, 20.6, 20.5. HRMS found = 370.1104 [M + 
Na]
 +
, calcd for [C12H18O6+Na] 
+ 
= 370.1108. 
Synthesis of compound 19 
O
OAc
AcO
OAc
OAc
H
N
O O
OCH3
19  
Monomethyl azelate (0.174 g, 0.863 mmol) was dissolved in DCM (5 mL) and added EDC.HCl 
(0.198 g, 1.035 mmol) and HOBt (0.116 g, 0.836 mmol) at 0° C to it. Compound 18 (0.300 g, 
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0.863 mmol) and triethylamine (0.104 g, 1.036 mmol) were added to the reaction mixture at 0 
°C. Stirred reaction mixture at 0 °C for 1 h. Continued stirring reaction mixture at rt overnight.  
Added ethyl acetate to the reaction mixture and washed organic layer with brine, 1N HCl, 5% 
NaHCO3 and lastly with brine, consecutively. The crude product was obtained after evaporation 
of solvent. The crude product was purified using flash silica gel column (10%→50% EtOAc in 
Hexane) to obtain compound 19 (0.217 g, 47%) as a colorless oil. Rf = 0.423 (70% EtOAc in 
hexane). 
1
H NMR (300 MHz, CDCl3): δ 6.23 (d, JH-H = 9.12, 1H), 5.45-5.43 (m, 1H), 5.27-5.21 
(m, 1H), 5.13-5.10 (m, 2H), 4.11-4.09 (m, 3H), 3.67 (s, 1H), 2.30 (t, JH-H =7.35, 1H), 2.15-2.00 
(m, 6H), 1.61-1.56 (br m, 4H), 1.31-1.30 (m, 6H). 
13
C NMR (75 MHz, CDCl3): δ  174.5, 174.6, 
171.6, 170.7, 170.4, 170.1, 78.7, 77.9, 77.4, 77.0, 72.6, 71.2, 68.7, 67.5, 61.4, 51.8, 36.9, 34.4, 
25.4, 25.1, 21.1, 21.0, 20.9, 21.0 .HRMS found = 554.2197 [M + Na]
 +
, calcd for [C12H18O6+Na] 
+ 
= 554.2207. 
Synthesis of compound 20 
O
OH
HO
OH
OH
H
N
O O
OH
20
 
Compound 19 (0.217 g, 0.408 mmol) was dissolved in 0.1 M methanolic NaOH (1 mL) and 
stirred at rt for 2.5 h. The reaction mixture was neutralized with 1N HCl. The solvent was rota 
evaporated and dried under vacuum to yield compound 20 (0.108 g, 76%) as a white solid. 
1
H 
NMR (300 MHz, CDCl3): δ  3.98 (s, 1H), 3.75-3.60 (br m, 3H), 2.4-2.29 (m, 3H), 1.60 (br s, 
4H), 1.13 (br s, 4H). 
13
C NMR (75 MHz, CDCl3): δ  174.2, 173.4, 80.7, 77.4, 75.0, 69.0, 61.2, 
52.0, 36.2, 34.1, 29.4, 29.3, 29.2, 25.7, 25.2. HRMS found = 372.1627 [M + Na]
 +
, calcd for 
[C12H18O6+Na] 
+ 
= 372.1628. 
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Synthesis of compound 15 
O
HO
N
H
O
O
N
H
15
OH
OH
HO
 
To a solution of compound 14 (0.048 g, 0.035 mmol), in dry DMF, added HOBt (0.005 g, 0.042 
mmol) and EDC (0.008g, 0.043 mmol) at 0 °C. Added compound 20 (0.012 g, 0.035 mmol) to 
the reaction mixture at 0 °C.  Reaction mixture was stirred at rt overnight. Crude product 15 was 
obtained as white solid after precipitation with acetone. HRMS found = 756.2635 [M +2+2Na]
 
+
/2 calcd [M +2+2Na]
 +
/2=755.2636. 
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